Neoplastic disease or syndrome
MONDO:0023370Either an isolated neoplasm or a syndrome with neoplasm as a major feature.
Also known as: neoplastic disease, neoplastic disorder
31093 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 1233 trials in this tab.
-
Can engineered immune cells outsmart Treatment-Resistant myeloma?
⭐️ CURE ⭐️ TerminatedThis early-stage trial is testing an experimental therapy called LCAR-BCDR, which uses a patient's own immune cells that have been engineered to recognize and attack a protein called BCMA found on myeloma cells. The study aims to see if this treatment is safe and tolerable, and w…
Phase: PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can a Chemo-Antibody combo beat a tough leukemia?
⭐️ CURE ⭐️ TerminatedThis phase II trial is testing whether adding the targeted antibody-drug inotuzumab ozogamicin to a standard chemotherapy regimen (Hyper-CVAD) improves outcomes for adults with B-cell acute lymphoblastic leukemia. The study enrolls people with newly diagnosed or recently remitted…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Aug 01, 2026 00:00 UTC
-
Can a gene make prostate cancer cells soak up radiation?
⭐️ CURE ⭐️ TerminatedThis phase 1 trial tests a gene therapy that helps prostate cancer cells absorb more radioactive iodine, potentially killing them while sparing healthy tissue. The study enrolls men whose prostate cancer returned after prior radiation therapy. Researchers aim to find the safest d…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Brain cancer vaccine trial halted: what we know
⭐️ VACCINE ⭐️ TerminatedThis study tested a vaccine called VBI-1901 in 70 people with recurrent glioblastoma, an aggressive brain cancer. The goal was to find a safe dose and see if the vaccine could boost the immune system against the tumor. The trial was terminated early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: VBI Vaccines Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:30 UTC
-
Experimental drug REC-2282 targets NF2 brain tumors in early trial
Disease control TerminatedThis study tested a drug called REC-2282 in people aged 12 and older with progressive meningiomas (brain tumors) linked to NF2 gene mutations. Participants took the drug or a placebo three times a week in cycles. The goal was to see if the drug could slow tumor growth. The trial …
Phase: PHASE2, PHASE3 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 18, 2026 02:00 UTC
-
New cancer drug trial hopes to reawaken immune cells against tumors
Disease control TerminatedThis trial tested an experimental drug called ASP1570 in adults with advanced solid tumors that had spread or could not be removed by surgery. The drug aims to help the body's immune T-cells attack tumors that have become resistant. The study was in two parts: first to find a saf…
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Experimental drug targets tough blood cancers in first human trial
Disease control TerminatedThis early-stage trial tested an experimental drug called SAR442257 in 47 adults with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might fight t…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Cancer drug olaparib tested for rare pancreatic tumor
Disease control TerminatedThis phase 2 trial tested the drug olaparib (Lynparza) in people with advanced pancreatic acinar cell carcinoma, a rare pancreatic cancer. Participants took olaparib pills twice daily for up to 2 years. The study was terminated early after enrolling only 5 people, so it is not kn…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug combo revive Immunotherapy's power against resistant tumors?
Disease control TerminatedThis trial is testing whether an experimental drug called NC410, when combined with the immunotherapy drug pembrolizumab, can safely and effectively treat people with advanced solid tumors that have not responded to standard immunotherapy or that are unlikely to respond. The stud…
Phase: PHASE1, PHASE2 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Nanoparticle chemo and DNA-Repair blocker join forces against tough cancers
Disease control TerminatedThis trial investigates a combination of two drugs: EP0057, a chemotherapy drug wrapped in a nanoparticle to help it reach cancer cells, and olaparib, which stops cancer cells from fixing DNA damage. The study includes adults with small cell lung cancer, bladder cancer, or prosta…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Experimental combo therapy for advanced cancer shows early promise but trial cut short
Disease control TerminatedThis early-stage trial tested a new drug (GEN1042) combined with radiation, with or without another immunotherapy (pembrolizumab), in people with metastatic solid tumors that had no standard treatment options. The goal was to see if the combination was safe and could shrink tumor…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a drug duo tame a rare eye cancer that has spread?
Disease control TerminatedThis trial is testing whether combining two drugs—pembrolizumab and lenvatinib—can help people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. Participants receive both drugs for up to two years. The study measures how long people liv…
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a daily pill shrink the spleen in myelofibrosis?
Disease control TerminatedThis phase 3 trial is testing an experimental oral drug, SAR302503, in people with a rare bone marrow disorder called myelofibrosis who have an enlarged spleen. Participants are randomly assigned to receive one of two doses of the drug or a placebo. The main goal is to see if the…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New antibody combo tackles solid tumors in early trial
Disease control TerminatedThis early-phase trial tested a new antibody drug, GEN1055, in 21 adults with advanced solid tumors. The goal was to check safety and find the right dose when used alone or with pembrolizumab (with or without chemotherapy). The study was stopped early, but results help guide futu…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Engineered immune cells take on viruses in cancer patients
Disease control TerminatedThis early-stage trial is testing whether genetically modified T-cells can safely control viral infections in cancer patients with weakened immune systems. The T-cells are designed to target specific viruses like CMV, BK virus, or COVID-19. The study involves 30 participants and …
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a targeted pill outperform chemo for bile duct cancer?
Disease control TerminatedThis trial is testing whether the targeted drug pemigatinib can slow or shrink a specific type of bile duct cancer (cholangiocarcinoma) that has a genetic change called FGFR2 rearrangement and cannot be removed by surgery. Participants will receive either pemigatinib as a daily p…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a protein calm the immune System's overreaction to cancer treatment?
Disease control TerminatedThis early-phase trial tests whether an experimental protein called CD24Fc can help people with advanced solid tumors recover from severe immune-related side effects caused by immunotherapy. These side effects occur when the immune system attacks healthy tissues. CD24Fc is design…
Phase: PHASE1, PHASE2 • Sponsor: Tianhong Li • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental lung inflammation treatment trial shuts down after just one patient
Disease control TerminatedThis phase 2 trial aimed to see if infliximab and intravenous immunoglobulin (IVIG) could help cancer patients with severe lung inflammation that didn't respond to steroids. Only one patient was enrolled before the study was terminated, so no meaningful results were obtained. The…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
Disease control TerminatedThis trial explores whether adding counseling, cognitive behavioural therapy, or hypnotherapy to nicotine replacement therapy can help cancer patients quit smoking before their surgery. The study includes adults with breast, digestive, gynecologic cancer, or melanoma who smoke da…
Phase: NA • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a pill target Hard-to-Treat ovarian cancers?
Disease control TerminatedThis early-stage trial is testing an experimental oral drug called NXP800 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, to find the safest dose and schedule, and then to see if the drug shows promise in specif…
Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Melanoma drug combo trial halted after just 3 patients
Disease control TerminatedThis study tested two drugs, encorafenib and binimetinib, given before surgery to people with stage IIIB-D melanoma that had spread to lymph nodes. The goal was to see if the drugs could shrink or eliminate the cancer before removal. The trial was stopped early after enrolling on…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Melanoma drug combo trial halted early – only 5 patients enrolled
Disease control TerminatedThis study tested whether adding hydroxychloroquine (a malaria drug) to standard targeted therapy (dabrafenib and trametinib) could help control advanced melanoma that had spread or could not be removed by surgery. It was designed for people with a specific gene mutation (BRAF V6…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Which Pre-Transplant chemo works best for MDS/AML? new trial aims to find out
Disease control TerminatedThis phase II trial tests two different chemotherapy combinations (treosulfan-based vs. clofarabine-based) given before a donor stem cell transplant in adults with myelodysplastic syndromes or acute myeloid leukemia. The goal is to see which regimen leads to better relapse-free s…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a One-Two punch of immune boosters revive cancer treatment?
Disease control TerminatedThis phase 2 trial tests whether combining high-dose IL-2 with nivolumab can shrink tumors in people with advanced melanoma or kidney cancer that has progressed despite prior anti-PD-1 therapy. Participants receive nivolumab and high-dose IL-2 in repeated cycles, and researchers …
Phase: PHASE2 • Sponsor: Gregory Daniels • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a custom vaccine train the body to fight ovarian cancer?
Disease control TerminatedThis phase 2 trial tests a personalized vaccine made from a patient's own immune cells fused with their tumor cells, given alongside GM-CSF injections and imiquimod cream. The goal is to see if this combination can trigger a stronger immune response against ovarian, fallopian tub…
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Liver cancer drug combo shows promise but study halted early
Disease control TerminatedThis study tested whether two immunotherapy drugs, nivolumab and ipilimumab, could shrink tumors in people with advanced liver cancer that had already been treated with another drug combination. The trial enrolled 15 adults whose cancer had spread or could not be removed by surge…
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can targeted radiation tame advanced prostate cancer? a registry aims to find out
Disease control TerminatedThis study collects real-world data from people with PSMA-positive metastatic castration-resistant prostate cancer who receive PSMA radionuclide therapy. The goal is to track patient characteristics, treatment responses, and survival outcomes. By gathering this information, resea…
Sponsor: Methodist Health System • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo shows early promise against Hard-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main g…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New pill shows promise in early trial for Hard-to-Treat breast cancer
Disease control TerminatedThis early-stage study tests a new oral drug, BBI-940, in people with advanced or metastatic breast cancer that has not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The study aims to find the safest dose and check for s…
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
Disease control TerminatedThis phase II pilot trial is asking whether combining the chemotherapy drug gemcitabine with the immunotherapy drug nivolumab can shrink tumors in people with advanced small cell lung cancer that has spread and no longer responds to initial treatment. The study enrolls about 14 a…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a common blood pressure drug help fight prostate cancer?
Disease control TerminatedThis pilot trial asks whether propranolol, a drug that blocks stress signals, can influence how prostate cancer cells survive or die. Men with prostate cancer scheduled for surgery will take propranolol before their operation. Researchers will then examine the removed prostate ti…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combos aim to boost survival in Hard-to-Treat cancers
Disease control TerminatedThis study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants received either standard chemotherapy or chemotherapy plus the imm…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Bladder cancer umbrella trial tests immunotherapy combos
Disease control TerminatedThis study tested several immunotherapy-based drug combinations in 272 people with advanced bladder cancer that had worsened after platinum chemotherapy. The goal was to see which combinations were safest and most effective at shrinking tumors or slowing the disease. Participants…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug combo enters human trials
Disease control TerminatedThis early-stage study tests a new drug called GSK3745417, given alone or with another drug (dostarlimab), in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. This is a…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a targeted drug make chemotherapy work again for ovarian cancer?
Disease control TerminatedThis trial is investigating whether adding an experimental drug called defactinib to standard chemotherapy (paclitaxel and carboplatin) can help treat ovarian cancer that has become resistant to platinum-based chemotherapy. The study includes people with recurrent ovarian, fallop…
Phase: PHASE1, PHASE2 • Sponsor: Michael McHale • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a targeted drug shrink rare salivary gland tumors?
Disease control TerminatedThis phase 2 trial is testing the drug rivoceranib in adults with recurrent or metastatic adenoid cystic carcinoma, a rare cancer that often starts in the salivary glands. The study aims to see if the drug can shrink tumors or slow the disease. Participants take rivoceranib table…
Phase: PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can an immune booster help chemotherapy fight metastatic breast cancer?
Disease control TerminatedThis trial tests whether adding an experimental immunotherapy called eftilagimod alpha to standard chemotherapy (paclitaxel) can help people with HER2-negative metastatic breast cancer live longer. The study first finds the best dose of eftilagimod alpha, then compares the combin…
Phase: PHASE2, PHASE3 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
A common diabetes drug may protect against hormone therapy's metabolic side effects
Disease control TerminatedThis phase 3 trial tests whether metformin, a standard diabetes medication, can prevent or reverse metabolic syndrome in men with prostate cancer who are starting androgen deprivation therapy (ADT). Metabolic syndrome—a cluster of conditions like high blood sugar, high blood pres…
Phase: PHASE3 • Sponsor: Canadian Urologic Oncology Group • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a MALT1 blocker tame Hard-to-Treat lymphoma?
Disease control TerminatedThis early-stage trial is testing an experimental drug called ONO-7018 in people with relapsed or refractory Non-Hodgkin lymphoma. The drug works by blocking a protein called MALT1 that may help lymphoma cells grow. The study aims to see if the drug is safe and tolerable, and how…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can an IDO1 inhibitor boost immunotherapy against liver cancer?
Disease control TerminatedThis trial is testing whether combining an experimental IDO1 inhibitor (BMS-986205) with the immunotherapy drug nivolumab can shrink tumors or slow disease progression in people with advanced liver cancer that cannot be surgically removed. The study enrolls adults whose cancer ha…
Phase: PHASE1, PHASE2 • Sponsor: Edward Kim • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can an immunotherapy-angiogenesis combo outshine standard chemo for advanced cervical cancer?
Disease control TerminatedThis phase 2 trial compares a new combination of camrelizumab (an immunotherapy) plus apatinib (a targeted therapy) against the standard chemotherapy plus bevacizumab as a first treatment for women with stage IVB, recurrent, or persistent cervical cancer. The study aims to see if…
Phase: PHASE2 • Sponsor: Sun Yat-Sen University Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can two drugs together tackle tough lung cancer?
Disease control TerminatedThis trial is testing whether combining two drugs—glumetinib and toripalimab—can help people with advanced non-small cell lung cancer that has not responded to or is no longer controlled by standard treatments. The study is enrolling adults whose cancer has a specific marker (PD-…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can an immune booster shrink Hard-to-Treat stomach tumors?
Disease control TerminatedThis phase 2 trial is testing whether toripalimab, an immunotherapy drug, can shrink tumors in people with advanced stomach or gastroesophageal junction cancer that has worsened after at least two prior treatments. Participants receive toripalimab every three weeks. The main goal…
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can extended poziotinib use keep cancer in check?
Disease control TerminatedThis trial offers continued treatment with poziotinib for people with non-small cell lung cancer or breast cancer who have already benefited from the drug in a previous study. The goal is to monitor safety and see how long the cancer remains controlled with extended use. Only pat…
Phase: PHASE2 • Sponsor: Spectrum Pharmaceuticals, Inc • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can an immune checkpoint blocker outperform interferon in keeping mucosal melanoma at bay?
Disease control TerminatedThis phase II trial tests whether toripalimab, an anti-PD-1 antibody, can prevent mucosal melanoma from returning after surgical removal better than high-dose interferon. Adults aged 18 to 75 whose melanoma was completely removed and who have not had prior adjuvant therapy are el…
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Rearranging the treatment timeline: could a new sequence of chemo and radiation spare rectal cancer patients from major surgery?
Disease control TerminatedThis trial is testing whether giving chemotherapy before the standard combination of chemo and radiation for rectal cancer could allow some patients to have a minor surgical procedure instead of a major one. The study enrolls adults with stage T2-T3 rectal cancer. The goal is to …
Phase: NA • Sponsor: Henry Ford Health System • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a Two-Pronged attack shrink Hard-to-Treat cancers?
Disease control TerminatedThis trial tests whether an experimental drug called XNW5004, which blocks a protein that helps cancer grow, can boost the effects of the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have stopped responding to standard treatments. The study inc…
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new nucleotide analogue boost cancer treatment?
Disease control TerminatedThis trial is testing an experimental drug called NUC-3373, a nucleotide analogue, in combination with standard cancer drugs for people with advanced solid tumors. The study has two parts: one combining NUC-3373 with pembrolizumab, and the other combining it with docetaxel. The g…
Phase: PHASE1, PHASE2 • Sponsor: NuCana plc • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a radioactive injection target bone tumors? a Dose-Finding trial aims to find out
Disease control TerminatedThis early-stage trial is testing an experimental drug called CycloSam (153-Sm-DOTMP), a radioactive compound that delivers radiation directly to bone tumors when injected. The study aims to find the safest dose in people aged 15 to 75 with solid tumors that have spread to the bo…
Phase: PHASE1 • Sponsor: QSAM Therapeutics, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Rectal cancer: could a 'Watch and Wait' strategy spare patients from major surgery?
Disease control TerminatedThis trial is testing whether a 'watchful waiting' approach after chemotherapy and radiation can safely avoid radical surgery in people with a certain type of rectal cancer. Participants receive chemotherapy (FOLFOX) followed by chemo-radiation, and those whose tumors completely …
Phase: NA • Sponsor: Henry Ford Health System • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can an oral chemo pill boost immunotherapy's power against lung cancer?
Disease control TerminatedThis phase 2 trial is testing whether adding an oral chemotherapy drug (CC-486, a form of azacitidine) to the immunotherapy pembrolizumab can help people with advanced non-small cell lung cancer who have already received one round of platinum-based chemotherapy. About 100 partici…
Phase: PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a Triple-Drug cocktail outsmart Treatment-Resistant colorectal cancer?
Disease control TerminatedThis phase 2 trial is testing whether adding an experimental drug called evorpacept to two existing cancer drugs (cetuximab and pembrolizumab) can shrink tumors in people with a specific type of advanced colorectal cancer that has not responded to prior treatments. The study enro…
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a lung cancer drug designed for one mutation work for another?
Disease control TerminatedThis phase II trial tests whether alectinib, a drug typically used for ALK-positive lung cancer, can shrink tumors or control disease in people with advanced non-small cell lung cancer that has a RET gene rearrangement and has progressed after prior treatment. Participants take a…
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Immunotherapy drug sintilimab takes on rare blood vessel cancer
Disease control TerminatedThis phase 2 trial tests whether sintilimab, an immunotherapy drug, can help control angiosarcoma—a rare cancer of the blood vessels—that is advanced, has spread, or has returned. Participants receive sintilimab intravenously, and the study measures how many have no cancer growth…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Double hormone blockade may tackle Hard-to-Treat breast cancer
Disease control TerminatedThis trial tests a combination of two drugs, elacestrant and onapristone, in people with a specific type of advanced or metastatic breast cancer that is fueled by the hormones estrogen and progesterone. The goal is to see if blocking both hormone signals at once is safe and can s…
Phase: PHASE1, PHASE2 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could a gel cut down on skin cancer surgeries? new trial investigates
Disease control TerminatedThis trial tests a gel called patidegib applied to the face twice daily for 9 months in people who develop many basal cell carcinomas (a common skin cancer) but do not have Gorlin syndrome. The goal is to see if the gel reduces the number of new skin cancers that would normally r…
Phase: PHASE2 • Sponsor: Sol-Gel Technologies, Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Liver-Friendly lymphoma treatment? new drug dosing study offers hope
Disease control TerminatedThis study tests the safety and best dose of loncastuximab tesirine, a targeted antibody-drug conjugate, in people with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma who also have moderate or severe liver impairment. The goal is to find a dosi…
Phase: PHASE1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Diabetes drug metformin could boost myeloma treatment
Disease control TerminatedThis phase 2 trial tests whether adding metformin — a common diabetes medication — to high-dose dexamethasone can improve outcomes for people with multiple myeloma that has returned or stopped responding to prior treatments. The study enrolls adults over 18 who have failed at lea…
Phase: PHASE2 • Sponsor: University of Campinas, Brazil • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for myelofibrosis patients who stop responding to standard therapy
Disease control TerminatedThis phase 2 trial tests an experimental drug called SAR302503 in people with myelofibrosis who have already been treated with ruxolitinib. The main goal is to see if the drug can shrink the spleen by at least 35% after six months of daily oral capsules. The study also tracks whe…
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Immunotherapy boosts radiation against early lung cancer
Disease control TerminatedThis study investigates whether adding the immunotherapy drug durvalumab to stereotactic body radiation therapy (SABR) improves outcomes for people with early-stage non-small cell lung cancer who cannot have surgery. Participants are randomly assigned to receive either SABR alone…
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug ATG-031 targets Hard-to-Treat cancers in first human trial
Disease control TerminatedThis study tests an experimental drug called ATG-031 in people with advanced solid tumors or B-cell non-Hodgkin lymphomas that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Participants receive ATG-031 by infusion…
Phase: PHASE1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Light-Activated implant could mend Cancer-Weakened bones without major surgery
Disease control TerminatedThis study tests a device called the Photodynamic Bone Stabilization System for treating painful fractures or impending fractures in the upper arm bone (humerus) caused by cancer that has spread to the bone. The device is inserted into the bone and hardened with light to provide …
Phase: NA • Sponsor: IlluminOss Medical, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Pre-surgery boot camp aims to cut complications in pancreatic cancer patients
Disease control TerminatedThis study tests a 4-week prehabilitation program combining exercise, nutritional supplements, and psychological support for patients with sarcopenia (muscle loss) who are about to have pancreatic cancer surgery. The goal is to see if this program reduces serious complications li…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Mesothelioma radiation trial ends early – few answers found
Disease control TerminatedThis study looked at whether adding targeted radiation therapy to surgery and chemotherapy could help people with early-stage pleural mesothelioma live longer. Only 16 people took part before the trial was stopped early, so we don't have clear results. The approach aimed to kill …
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered immune cells take aim at Mesothelin-Positive tumors
Disease control TerminatedThis trial tests a new cell therapy called TC-510 for people with advanced cancers that have a protein called mesothelin on their surface, including mesothelioma, ovarian cancer, and pancreatic cancer. TC-510 uses a patient's own immune cells, which are genetically modified to be…
Phase: PHASE1, PHASE2 • Sponsor: TCR2 Therapeutics • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a Three-Pronged attack keep High-Risk leukemia at bay?
Disease control TerminatedThis phase 1 trial is testing whether a combination of two drugs (venetoclax and azacitidine) followed by donor immune cell infusions can prevent relapse in people with very high-risk acute myeloid leukemia (AML) who have already received a stem cell transplant. The study enrolls…
Phase: PHASE1 • Sponsor: Antonio M Jimenez Jimenez • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Liver cancer radiation trial halted after just one patient
Disease control TerminatedThis study aimed to see if adding focused radiation to standard chemotherapy helps people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. Only one person enrolled before the trial was stopped early, so no meaningful conclusions can…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Light-Activated cream could slow growth of NF1 skin tumors
Disease control TerminatedThis trial tests whether a light-activated cream (Levulan Kerastick) followed by red light therapy can slow the growth of benign skin tumors called neurofibromas in people with neurofibromatosis type 1 (NF1). About 30 participants aged 14 and older with superficial tumors on the …
Phase: PHASE2 • Sponsor: Donald Basel • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Genetic clues could personalize breast cancer treatment
Disease control TerminatedThis study looks at genetic changes in postmenopausal women with a common type of advanced breast cancer (HR+ HER2-). Participants first receive ribociclib plus letrozole; those with a specific mutation (PIK3CA) may later switch to alpelisib plus fulvestrant. The goal is to track…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug OB318 enters human testing for Hard-to-Treat cancers
Disease control TerminatedThis Phase 1 trial tests an experimental drug called OB318 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and to understand how the body processes the drug. Researchers will also look for early signs tha…
Phase: PHASE1 • Sponsor: Oneness Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control TerminatedThis trial tests a new therapy called CART123 for adults with acute myeloid leukemia (AML) that has not responded to standard treatments or has returned after treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cell…
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Targeted radiation zaps Hard-to-Treat cancers in early trial
Disease control TerminatedThis early-stage trial tests a new drug, [177Lu]Lu-EVS459, that delivers radiation directly to cancer cells in people with advanced ovarian or lung cancers. The study aims to see if the treatment is safe and tolerable, and to get an early look at whether it can shrink tumors. Par…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New cancer pill shows early promise, but trial halted
Disease control TerminatedThis early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early,…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
CAR-T therapy for myeloma shows promise in early trial
Disease control TerminatedThis early-stage study tested a new type of immunotherapy called CAR-T cells that target a protein called BCMA on multiple myeloma cells. The treatment involved taking a patient's own immune cells, engineering them to attack the cancer, and infusing them back. The study included …
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Immunotherapy boosts chemo in aggressive breast cancer trial
Disease control TerminatedThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy before surgery can help the immune system fight triple-negative breast cancer more effectively. About 15 people with early-stage (stage II or III) triple-negative breast cancer will receive …
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Proton beam therapy plus chemo aims to improve Post-Surgery treatment for advanced endometrial cancer
Disease control TerminatedThis phase 2 trial tests a new approach called UPPROACH for people with loco-regionally advanced endometrial cancer who have had surgery. The treatment combines intensity-modulated proton beam therapy (IMPT) with standard chemotherapy (carboplatin and paclitaxel) given at the sam…
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Real-World study tracks Selumetinib's impact on NF1 tumors in children
Disease control TerminatedThis study observes children aged 3 to 18 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas and are starting treatment with selumetinib. Researchers will track how well the drug shrinks or stabilizes tumors, how long patients stay on tre…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Radiation and immunotherapy join forces against hard-to-treat liver cancer
Disease control TerminatedThis trial tests whether adding a precise, internal radiation treatment (166Holmium microspheres) to standard immunotherapy (atezolizumab and bevacizumab) can shrink liver tumors that cannot be surgically removed. About 10 adults with unresectable hepatocellular carcinoma will re…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Drug cocktail aims to stall pancreatic cancer in patients who have run out of options
Disease control TerminatedThis phase 2 trial tests whether combining two drugs—erlotinib and everolimus—can slow the growth of advanced pancreatic cancer in patients who have already received at least one prior treatment. The study enrolls people with unresectable or metastatic pancreatic adenocarcinoma a…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
Disease control TerminatedThis early-phase trial tests a personalized cell therapy for people with metastatic pancreatic cancer. A patient's own T-cells are genetically modified to recognize and attack mesothelin, a protein found on many pancreatic cancer cells. Before receiving the modified cells, patien…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug SLC-3010 takes on advanced solid tumors
Disease control TerminatedThis trial studies a new drug called SLC-3010, given alone or with chemotherapy (gemcitabine), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. The study is in two par…
Phase: PHASE1, PHASE2 • Sponsor: Selecxine • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Radioactive lipiodol takes aim at inoperable liver tumors
Disease control TerminatedThis phase II trial tests a targeted radiation therapy called 188Re-SSS lipiodol for people with liver cancer that cannot be surgically removed. The treatment delivers radiation directly to the tumor through the liver's blood vessels. The study aims to see how many patients' tumo…
Phase: PHASE2 • Sponsor: Center Eugene Marquis • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Pre-Surgery drug cocktail aims to wipe out rectal cancer
Disease control TerminatedThis trial investigates whether giving a combination of bevacizumab (a drug that blocks blood vessel growth to tumors) and chemotherapy before surgery can eliminate all signs of cancer in people with stage II or III rectal cancer. Participants receive the treatment before their p…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a drug cocktail halt bone Cancer's spread after radiation?
Disease control TerminatedThis study tests whether adding a three-drug combination (ixazomib, lenalidomide, and dexamethasone) to zoledronic acid after radiation therapy can prevent solitary plasmacytoma of bone from turning into multiple myeloma. Participants receive either the drug combo plus zoledronic…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Two-Drug combo aims to outsmart resistant hodgkin lymphoma
Disease control TerminatedThis phase 2 study tests whether combining magrolimab and pembrolizumab can shrink or eliminate tumors in people with classic Hodgkin lymphoma that has come back or not responded to at least two prior treatments. Magrolimab targets a 'don't eat me' signal on cancer cells, while p…
Phase: PHASE2 • Sponsor: Ranjana Advani • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo aims to shrink rectal tumors before surgery
Disease control TerminatedThis trial investigates whether combining two drugs, niraparib and dostarlimab, with a short course of radiation before surgery can help treat locally advanced rectal cancer. The study first finds a safe dose of niraparib, then checks how well the combination shrinks the tumor. P…
Phase: PHASE1 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Radiation and immunotherapy combo before lung cancer surgery shows promise in early trial
Disease control TerminatedThis phase 2 trial tests whether a low dose of radiation (12 Gy in 3 fractions) combined with one dose of the immunotherapy drug durvalumab can boost the immune system's attack on lung cancer cells before surgery. The study enrolls people with stage 2 or 3 non-small cell lung can…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immunotherapy combo for liver cancer shows early promise but trial halted
Disease control TerminatedThis phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) given before and after a procedure called electroporation for people with advanced hepatocellular carcinoma (liver cancer) that could still be treated with curative intent. The study aimed to see if adding nivolu…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental combo for tough leukemia hits early snag
Disease control TerminatedThis early-stage trial tested a combination of two targeted drugs—tagraxofusp-erzs and gemtuzumab ozogamicin—in 7 patients with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find a safe dose and see if the combination could control the d…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Experimental vaccine aims to shrink colorectal tumors before surgery
Disease control TerminatedThis trial tested a vaccine called PD1-Vaxx given before surgery to people with a specific type of colorectal cancer (MSI-high). The goal was to see if the vaccine could shrink tumors, measured by how many cancer cells remained after treatment. Only 3 people took part, and the st…
Phase: PHASE2 • Sponsor: University of Southampton • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for rare uterine cancer? trial tests avastin with chemo
Disease control TerminatedThis phase 3 trial tested whether adding bevacizumab (Avastin) to standard chemotherapy (docetaxel and gemcitabine) helps people with advanced or recurrent uterine leiomyosarcoma. The study enrolled 107 participants but was terminated early. Researchers measured how long patients…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could an extra antibody slow HER2+ breast cancer spread?
Disease control TerminatedThis trial investigates whether adding bevacizumab (Avastin) to standard first-line chemotherapy plus trastuzumab (Herceptin) helps people with HER2-positive metastatic breast cancer. Participants receive either bevacizumab or a placebo alongside their regular treatment. The main…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Breast cancer drug showdown: which CDK4/6 inhibitor works best?
Disease control TerminatedThis phase 3 trial aimed to compare two drugs, ribociclib and palbociclib, in people with a specific type of advanced breast cancer (HR+/HER2- with HER2-enriched features). Participants received one of the drugs combined with hormone therapy. The goal was to see which combination…
Phase: PHASE3 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New chemo combo targets Hard-to-Treat liver cancer
Disease control TerminatedThis early-phase trial tested a two-step chemotherapy approach for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. First, patients received a standard chemo mix (mFOLFIRINOX) through the veins. Then, they got a second chemo …
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a common blood pressure drug shrink kidney tumors?
Disease control TerminatedThis pilot study tested whether propranolol, a beta-blocker, could shrink or stabilize kidney angiomyolipomas in people with tuberous sclerosis. Only 2 participants were enrolled before the trial was terminated, so the results are very limited. The goal was to find a less invasiv…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental drug combo for rare sarcoma shows promise, but trial halted early
Disease control TerminatedThis phase 3 trial tested whether adding ADI-PEG 20 to standard chemotherapy (gemcitabine and docetaxel) could help people with advanced leiomyosarcoma, a rare soft tissue cancer. The study planned to enroll 218 participants whose cancer had progressed after prior treatment. Unfo…
Phase: PHASE3 • Sponsor: Polaris Group • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Laser plus gel: new hope for port wine stains?
Disease control TerminatedThis study tested whether adding timolol gel to pulsed dye laser treatment could improve results for port wine stains on children's faces. Twenty-five children aged 6 months to 18 years were enrolled, but the study was stopped early. The goal was to see if the combination led to …
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Ovarian cancer combo trial halted early
Disease control TerminatedThis study tested a new drug, CRLX101, combined with standard chemotherapy (paclitaxel) in 30 women with ovarian cancer that came back or didn't go away. The goal was to find the safest dose and see if the combination helped shrink tumors. The trial was terminated early, so resul…
Phase: PHASE1, PHASE2 • Sponsor: NewLink Genetics Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental HER2 cancer drug trial halted early
Disease control TerminatedThis was an early-phase study testing a new drug called XMT-2056 in people with advanced solid tumors that have a protein called HER2. The trial aimed to find a safe dose and check for side effects. It was terminated early, so the full results are not available.
Phase: PHASE1 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo targets metastatic breast cancer
Disease control TerminatedThis early-stage study tested the safety and best dose of combining the drugs RAD001 and docetaxel in 15 people with metastatic breast cancer. The goal was to find a dose that is tolerable while potentially controlling the disease. The study was terminated early, so results are l…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cancer combo trial ends early
Disease control TerminatedThis early-stage study tested a new drug called CLN-617, alone or with the immunotherapy Keytruda, in 23 adults with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and find the right dose. However, the trial was terminated, so fu…
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cancer therapy targets tough tumors with radioactive precision
Disease control TerminatedThis early-stage trial tested a two-step radioimmunotherapy combining GD2-SADA and 177Lu-DOTA in patients with recurrent or metastatic solid tumors, including small cell lung cancer, high-risk neuroblastoma, sarcoma, and melanoma. The goal was to assess safety and find the right …
Phase: PHASE1 • Sponsor: Y-mAbs Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug combo tested in tiny trial – but halted early
Disease control TerminatedThis early-stage trial tested an experimental drug called BND-35, alone or combined with nivolumab or cetuximab, in 12 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was te…
Phase: PHASE1 • Sponsor: Biond Biologics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New universal cell therapy shows promise for Hard-to-Treat blood cancer
Disease control TerminatedThis early-stage study tested a new type of cell therapy called LUCAR-B68 in 8 adults with multiple myeloma that had come back or stopped responding to treatment. The therapy targets a protein called BCMA on cancer cells and is designed to be used without needing to match the pat…
Phase: PHASE1 • Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill for ulcerative colitis shows promise, but trial halted early
Disease control TerminatedThis study tested an oral medication, NX-13, in 81 adults with moderate to severe ulcerative colitis. Participants received either NX-13 or a placebo for 12 weeks, with a long-term follow-up option. The trial was terminated early, so the full results are not available, but the da…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called PRS-344/S095012 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was stopped early, and only 46 people took part.
Phase: PHASE1, PHASE2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cell therapy targets Hard-to-Treat sarcoma
Disease control TerminatedThis phase 2 trial tested a new cell therapy called TAEST16001 in 8 adults with advanced soft tissue sarcoma that had stopped responding to standard treatments. The therapy uses specially engineered immune cells to attack cancer cells that carry a specific marker (NY-ESO-1) in pa…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Targeted drug shows promise for Hard-to-Treat lung cancer
Disease control TerminatedThis study tested a drug called poziotinib in 648 people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 mutations). The goal was to see if the drug could shrink tumors. The study was stopped early, but results showed some patients…
Phase: PHASE2 • Sponsor: Spectrum Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New proton therapy aims to save eyes from removal in large melanoma cases
Disease control TerminatedThis study tested two different proton therapy schedules for people with large choroidal melanomas (eye cancer) that would normally require removal of the eye. The goal was to see if a gentler radiation schedule could control the tumor and avoid severe side effects, allowing pati…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Promising drug trial for rare pancreatic cancer stopped early
Disease control TerminatedThis study tested whether the drug surufatinib could help prevent pancreatic neuroendocrine tumors from coming back after surgery. The trial was planned for many participants but was stopped early with only 6 people enrolled. Because it ended early, we don't have clear answers on…
Phase: PHASE2 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental combo for Hard-to-Treat cancers shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a combination of two oral drugs, mirdametinib and brimarafenib, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. Th…
Phase: PHASE1, PHASE2 • Sponsor: SpringWorks Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo aims to spare seniors from chemo
Disease control TerminatedThis phase 2 trial tested a combination of two drugs, venetoclax and rituximab, as a first treatment for people over 60 with mantle cell lymphoma. The goal was to see if this chemo-free approach could shrink or control the cancer. However, the study was stopped early after enroll…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental combo for lung cancer shows promise but study cut short
Disease control TerminatedThis phase 2 trial tested a combination of two drugs—NT-I7 and atezolizumab—in people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combo could shrink tumors. However, the study was stopped early and only enrolled 33 out of …
Phase: PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Eye drop gel shows promise for skin graft healing, but trial stalls
Disease control TerminatedThis study tested whether applying 0.25% timolol gel (a beta-blocker eye drop used for glaucoma) to skin grafts could improve healing and appearance after skin cancer surgery. Researchers planned to enroll 82 patients but stopped early with only 10 participants. The goal was to s…
Phase: PHASE2, PHASE3 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for myelofibrosis patients who failed standard therapy?
Disease control TerminatedThis study tested a drug called selinexor in 17 people with a rare bone marrow cancer (myelofibrosis) that did not respond to or could not tolerate standard JAK inhibitor treatments. The main goal was to see if the drug could shrink an enlarged spleen by at least 35%. The trial w…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental combo for resistant leukemia shows early promise but trial halted
Disease control TerminatedThis pilot study tested a new drug called sEphB4-HSA combined with standard chemotherapy (azacitidine or decitabine) in 7 patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia that had returned or not responded to prior treatment. The …
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental Artery-Directed chemo for rare brain tumors: tiny trial ends early
Disease control TerminatedThis early-phase trial tested giving chemotherapy drugs directly into the brain's arteries to treat two rare types of choroid plexus tumors. The goal was to shrink the tumor before a second surgery. Only 1 person was enrolled, and the study was terminated, so we have very little …
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a common chemo drug boost the benefits of palliative radiation for advanced cancer?
Disease control TerminatedThis phase 3 trial tests whether adding the chemotherapy drug carboplatin to standard palliative radiotherapy helps control tumor growth and reduce pain better than radiotherapy alone. The study includes adults with advanced lung or head and neck cancer who need palliative radiat…
Phase: PHASE3 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental combo therapy for tough lymphoma shows promise but trial halted early
Disease control TerminatedThis Phase 2 trial tested a two-step treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by an infusion of CAR-T cells (a type of immune cell therapy). The goal was to se…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Kaposi's sarcoma drug trial halted early – what we know
Disease control TerminatedThis phase II trial tested the drug everolimus in 11 people with classic or endemic Kaposi's sarcoma, a rare skin cancer linked to a virus. The goal was to see if the drug could shrink tumors after 6 months. The study was terminated early, so the full results are not available.
Phase: PHASE2 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Weight loss and hormone pill tested for fertility-sparing cancer treatment – but trial stopped early
Disease control TerminatedThis study tested whether combining weight management (diet and exercise guidance) with a daily hormone pill (megestrol acetate) could help obese patients with early-stage endometrial cancer who want to preserve their fertility. The goal was to see if the cancer would completely …
Phase: PHASE2, PHASE3 • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New vaccine combo aims to supercharge immune attack on breast cancer
Disease control TerminatedThis study tested whether adding a HER2-targeting vaccine (VRP-HER2) to the immunotherapy drug pembrolizumab could boost the immune system's attack on advanced HER2-positive breast cancer. Eight participants were randomly assigned to receive the vaccine alone, pembrolizumab alone…
Phase: PHASE2 • Sponsor: Herbert Lyerly • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Cancer combo trial halted early after enrolling only 5 patients
Disease control TerminatedThis study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Cancer drug trial halted after just one patient
Disease control TerminatedThis phase 2 trial tested whether the immunotherapy drug atezolizumab could shrink head and neck skin cancers that had spread to lymph nodes before surgery. Only 1 person enrolled before the study was terminated early. The goal was to see if the drug could eliminate all cancer ce…
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Lung cancer drug trial halted early: what happened?
Disease control TerminatedThis study tested an experimental drug called cofetuzumab pelidotin for people with a specific type of advanced lung cancer (non-small cell lung cancer) that had returned after other treatments. The drug was designed to target a protein called PTK7 found on cancer cells. The stud…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental cancer drug study halted early
Disease control TerminatedThis early-stage study tested a new drug called PF-07284892, alone or with other medicines, in people with advanced solid tumors that had specific genetic changes. The goal was to find the safest dose and check for side effects. The study was stopped early, so results are limited…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental melanoma cocktail trial halted early
Disease control TerminatedThis early-stage trial tested a combination of an experimental fusion protein (hu14.18-IL2), radiation, and two immunotherapy drugs (nivolumab and ipilimumab) in people with advanced melanoma that couldn't be surgically removed. The goal was to find the safest dose and check for …
Phase: PHASE1, PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental cancer combo tested in tiny, terminated trial
Disease control TerminatedThis early-stage trial tested a new drug called 2X-121, alone and combined with another drug called dovitinib, in 14 people with advanced solid tumors. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limited and no c…
Phase: PHASE1 • Sponsor: Allarity Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Lung cancer gene therapy trial halted early
Disease control TerminatedThis early-stage trial tested a new gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer who had already received treatment. The goal was to see if the combination was sa…
Phase: PHASE1 • Sponsor: Genprex, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Cancer drug combo tested for rare gene mutation – but trial stopped early
Disease control TerminatedThis study tested two drugs, niraparib and bevacizumab, alone or together, in people with recurrent endometrial or ovarian cancer that has a specific gene change called ARID1A. The goal was to see if the drugs could shrink tumors. However, the trial was stopped early after enroll…
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Heart drug may tame baby blood vessel growth
Disease control TerminatedThis study tested if the beta-blocker propranolol could control the growth of infantile hemangiomas (non-dangerous blood vessel growths) in babies under 4 months old. The trial was terminated early and only enrolled 14 infants. The goal was to measure changes in hemangioma thickn…
Phase: PHASE2, PHASE3 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Focused ultrasound trial for rare sarcoma halted early
Disease control TerminatedThis study tested whether focused ultrasound could partially destroy a rare soft-tissue cancer called undifferentiated pleomorphic sarcoma and boost the body's immune response. Only 5 people were enrolled before the trial was terminated. The main goal was to check safety and see …
Phase: NA • Sponsor: Matthew Bucknor • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New light therapy for brain cancer shows promise in early trial
Disease control TerminatedThis trial tested a light-activated drug called PD L 506 (5-aminolevulinic acid) in 17 adults with a type of aggressive brain tumor called glioblastoma that could not be fully removed by surgery. The drug is given by mouth and then activated by a laser inserted into the brain to …
Phase: PHASE2 • Sponsor: photonamic GmbH & Co. KG • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising combo for IDH1 leukemia hits early snag – trial stopped
Disease control TerminatedThis early-phase trial tested whether adding the targeted drug ivosidenib to standard FLAG chemotherapy could help people with a specific genetic form of acute myeloid leukemia (IDH1-mutant AML). The study aimed to find the best dose and check for side effects in patients whose c…
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough blood cancers: early trial of ONO-7018 begins
Disease control TerminatedThis early-stage study tested a new drug called ONO-7018 in 9 adults with non-Hodgkin lymphoma or chronic lymphocytic leukemia that had returned or stopped responding to other treatments. The main goal was to find a safe dose and check for side effects. The study was stopped earl…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
CML drug combo aims for Treatment-Free remission, but trial stalls
Disease control TerminatedThis phase 3 trial tested whether adding asciminib to the standard drug imatinib could help people with chronic myeloid leukemia (CML) achieve a deep remission and safely stop all medication. Only 8 patients were enrolled before the study was terminated early, making it too small…
Phase: PHASE3 • Sponsor: Sarit Assouline • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Lung cancer drug combo study halted after just 4 patients
Disease control TerminatedThis study aimed to see if combining two drugs, bemcentinib and pacritinib, could help people with advanced lung adenocarcinoma that had stopped responding to other treatments. Only 4 patients were enrolled before the study was terminated early, so no conclusions can be drawn abo…
Phase: PHASE1, PHASE2 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental NK cell therapy for blood cancers hits early hurdle
Disease control TerminatedThis early-stage study tested a new drug called SAR445514, which helps the body's natural killer (NK) cells attack cancer cells in people with multiple myeloma or light-chain amyloidosis that had returned or stopped responding to other treatments. The study was terminated early, …
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Mini transplant shows promise for blood cancers – but trial ended early
Disease control TerminatedThis study tested a reduced-intensity bone marrow transplant, or 'mini transplant,' for people with blood cancers like lymphoma and leukemia. The transplant used marrow from a relative and was combined with chemotherapy drugs to help the donor cells take hold. Only 15 people took…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo tested for tough bile duct cancers
Disease control TerminatedThis study tested a new drug called LSTA1 added to standard treatment for people with advanced bile duct or gallbladder cancer. The goal was to see if the combination is safe and works better than standard treatment alone. The trial was stopped early, and results are not yet avai…
Phase: PHASE2 • Sponsor: Lisata Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Bladder cancer combo therapy trial cut short – what we know
Disease control TerminatedThis phase 2 trial tested whether adding the immunotherapy avelumab to standard chemotherapy (gemcitabine-cisplatin) helps people with advanced bladder cancer that has spread. The study planned to enroll 65 patients but was terminated early. Researchers measured tumor shrinkage a…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Early trial of lenalidomide after transplant for myeloma stopped early
Disease control TerminatedThis phase 1 trial tested the safety of the drug lenalidomide as maintenance therapy after a reduced-intensity stem cell transplant for multiple myeloma. Only 13 people took part, and the study was terminated early. The goal was to see if lenalidomide could help prevent the cance…
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Mistletoe vs. chemo: bladder cancer trial halted early
Disease control TerminatedThis study aimed to see if a mistletoe extract placed directly into the bladder could delay cancer return better than standard chemotherapy in 174 people with early-stage bladder cancer. The trial was stopped early, so results are limited. The approach focuses on controlling the …
Phase: PHASE3 • Sponsor: Abnoba Gmbh • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Promising combo therapy for head and neck cancer hits early snag
Disease control TerminatedThis phase II trial tested two drug combinations—ibrutinib plus nivolumab or ibrutinib plus cetuximab—in patients with recurrent or metastatic head and neck squamous cell carcinoma. The goal was to see if these combinations could shrink tumors or slow disease progression. However…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Cancer-Killing virus tested in humans for first time
Disease control TerminatedThis early-phase trial tested a new immunotherapy called BI 1821736 in 10 adults with advanced solid tumors that had not responded to standard treatments. BI 1821736 is a specially designed virus meant to kill cancer cells and help the immune system fight the cancer. Participants…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Spine tumor bleeding study halted after just 4 patients
Disease control TerminatedThis study aimed to see if a procedure called angiographic embolization (blocking blood vessels feeding spine tumors) before surgery could reduce blood loss during the operation. It included adults aged 18-75 with spine metastases that had moderate blood supply. The study was sto…
Phase: NA • Sponsor: Istituto Ortopedico Rizzoli • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Immune booster added to standard cervical cancer treatment shows promise in early trial
Disease control TerminatedThis study tested adding the immune-boosting drug pembrolizumab to standard chemoradiation for people with advanced cervical cancer. The goal was to see if the combination is safe and to find the best dose. Only one person was enrolled before the study was stopped early, so resul…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
Disease control TerminatedThis phase III trial compared two radiation strategies for cancer that had spread to the brain and returned in new spots after initial radiosurgery. One group received focused radiation only to the new tumors, while the other received whole brain radiation that avoided the memory…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for tough lung cancer? trial tests targeted drug against chemo
Disease control TerminatedThis phase 3 trial compared an experimental drug called tusamitamab ravtansine to the chemotherapy docetaxel in 389 people with advanced non-small cell lung cancer that had a specific marker (CEACAM5). The study aimed to see if the new drug could slow cancer growth or improve sur…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental cancer drug tested in patients with no other options
Disease control TerminatedThis study tested a drug called BM7PE immunotoxin in 14 people with colorectal cancer that had spread and was no longer responding to standard chemotherapy. The goal was to find a safe dose and see if it could help patients live longer. The study was stopped early, so we have lim…
Phase: PHASE1, PHASE2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Radioactive beads offer hope for frail cancer patients
Disease control TerminatedThis study tested a treatment called radioembolization for elderly or frail patients whose colorectal cancer has spread only to the liver and cannot be removed by surgery. Instead of standard chemotherapy, tiny radioactive beads are injected into the liver's blood supply to targe…
Phase: PHASE2 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug combo for advanced breast cancer shows promise but trial halted early
Disease control TerminatedThis phase 2 study tested a new drug called lerociclib combined with standard hormone therapy in 100 people with advanced HR+/HER2- breast cancer. The goal was to see if the combination is safe and effective. However, the trial was terminated early, so the full results are not av…
Phase: PHASE2 • Sponsor: EQRx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for tough leukemias? trial of vodobatinib begins, then stops
Disease control TerminatedThis study tested a new drug called Vodobatinib (K0706) in people with chronic myeloid leukemia or a related leukemia who had not responded to at least three other treatments. The trial was split into parts: first in healthy volunteers to check safety, then in patients to find th…
Phase: PHASE1, PHASE2 • Sponsor: Sun Pharma Advanced Research Company Limited • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Blood cancer transplant study tests safer GVHD prevention
Disease control TerminatedThis phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for elderly myeloma patients: Steroid-Free combo shows promise
Disease control TerminatedThis study tested a combination of two drugs, ixazomib and daratumumab, without using steroids (dexamethasone) in elderly patients (65 and older) whose multiple myeloma had returned after previous treatments. The goal was to see if this gentler approach could effectively control …
Phase: PHASE2 • Sponsor: University Hospital, Caen • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo trial for tough pancreatic cancer shows early promise
Disease control TerminatedThis early-stage trial tested a combination of two drugs, trametinib and hydroxychloroquine, in 25 adults with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and understand side effects. The study was stopped early, so r…
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Sound waves and drug team up against brain tumors
Disease control TerminatedThis early-phase trial tested a combination of a drug called aminolevulinic acid (ALA) and focused ultrasound to treat recurrent high-grade glioma, an aggressive brain cancer. The study aimed to see if this sonodynamic therapy could safely damage tumor cells. Only 10 participants…
Phase: EARLY_PHASE1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Cancer drug niraparib tested before prostate surgery – early trial stopped
Disease control TerminatedThis phase II trial tested the drug niraparib (Zejula) in 11 men with high-risk prostate cancer that had not spread. All men had specific DNA repair gene mutations. They took niraparib before having their prostate removed surgically. The goal was to see if the drug could eliminat…
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Personalized cell therapy shows promise but trial ends early
Disease control TerminatedThis study tested a personalized treatment using immune cells taken from a patient's own tumor, called tumor-infiltrating lymphocytes (TIL). The cells were grown in a lab and given back to the patient to fight their cancer. The trial included people with advanced melanoma, head a…
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New way to deliver chemo directly to brain tumors tested in small study
Disease control TerminatedThis early-phase trial tested a single dose of the cancer drug temsirolimus, given directly into the brain's blood supply, for people with recurrent high-grade glioma (a fast-growing brain tumor). Only 5 participants were enrolled, and the study was terminated early. The main goa…
Phase: EARLY_PHASE1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug HEC89736 tested in blood cancer patients – but trial stopped early
Disease control TerminatedThis early-phase trial tested an experimental drug called HEC89736 in people with B-cell blood cancers that had returned or stopped responding to treatment. The study aimed to check the drug's safety and how the body processes it. Only 5 people took part before the trial was term…
Phase: PHASE1 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental combo for tough prostate cancer shows early promise but trial halted
Disease control TerminatedThis study tested a combination of two drugs, bortezomib and docetaxel, in 15 men with advanced prostate cancer that had stopped responding to hormone therapy. The goal was to see if the combo could lower PSA levels and ease pain. The trial was terminated early, so the findings a…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New prostate cancer combo trial ends early
Disease control TerminatedThis study tested a new drug called exicorilant (CORT125281) combined with enzalutamide in men with metastatic castration-resistant prostate cancer. The goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited. It involved 39…
Phase: PHASE1, PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug DT-9081 tested in early trial – but study stopped early
Disease control TerminatedThis early-phase trial tested an oral drug called DT-9081 in 29 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so full results are not available.
Phase: PHASE1 • Sponsor: Domain Therapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Lung cancer drug combo trial halted midway
Disease control TerminatedThis study tested a new combination of two drugs (ociperlimab and tislelizumab) against a standard drug (pembrolizumab) for people with advanced non-small cell lung cancer that had not been treated before. The trial aimed to see if the combo could help patients live longer or slo…
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental cancer drug combo trial halted early
Disease control TerminatedThis phase 3 trial tested a drug called A140 (similar to cetuximab) combined with chemotherapy (mFOLFOX6) as a first treatment for people with a specific type of advanced colorectal cancer (RAS wild-type). The study planned to enroll 570 people in China but was terminated early w…
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New stoma technique aims to ease bowel troubles after rectal cancer surgery
Disease control TerminatedThis study tested a new type of temporary colostomy (a surgical opening in the belly) for people having rectal cancer surgery. The goal was to see if it could reduce bowel problems and kidney injury compared to the usual stoma. Only 16 patients were enrolled before the study was …
Phase: NA • Sponsor: Umeå University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental combo for tough leukemia shows promise in early trial
Disease control TerminatedThis pilot study tested adding the targeted drug venetoclax to standard chemotherapy (FLAG or CLAG) for people with newly diagnosed secondary acute myeloid leukemia (sAML), a challenging blood cancer. The goal was to see if the combination could improve complete remission rates. …
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Can a simple drink before surgery tame blood sugar spikes in colorectal cancer patients?
Disease control TerminatedThis study tested whether drinking a mix of branched-chain amino acids (BCAAs) a few hours before colorectal cancer surgery could help prevent high blood sugar afterward. About 79 patients were split into two groups: one got a BCAA drink, the other plain water. The goal was to se…
Phase: NA • Sponsor: Sun Peng • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New cancer drug trial halted early: what we know
Disease control TerminatedThis early-stage study tested a new drug called NM6603 in 17 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The trial was ended early, so results are limited.
Phase: PHASE1 • Sponsor: NucMito Pharmaceuticals Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cell therapy for advanced cancers shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a personalized cell therapy called GT101 in 10 adults with advanced solid tumors that had spread or come back. The treatment involved collecting the patient's own immune cells from the tumor, growing them in a lab, and giving them back along with che…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Liver cancer immunotherapy study halted early
Disease control TerminatedThis study tested two immunotherapy drugs (durvalumab and tremelimumab) in people with liver cancer who were waiting for a liver transplant. The goal was to see if the drugs could safely shrink tumors and control the disease without causing organ rejection. Only 8 people took par…
Phase: PHASE2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New chemo combo for stomach cancer shows promise in early trial
Disease control TerminatedThis study tested a combination of chemotherapy drugs for people with stomach cancer that has spread inside the belly. The treatment involved giving one drug directly into the abdomen and through a vein, plus a second drug taken by mouth. The goal was to see if this approach coul…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a cholesterol drug boost immunotherapy in lung cancer?
Disease control TerminatedThis study tested whether adding evolocumab (a cholesterol-lowering drug) to standard immunotherapy (nivolumab and ipilimumab) is safe and helps the immune system fight advanced non-small cell lung cancer. It included 19 people with newly diagnosed metastatic lung cancer who had …
Phase: PHASE2 • Sponsor: Eziafa Oduah, MD, PhD, MPH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Lung cancer combo trial halted after just one patient
Disease control TerminatedThis phase 2 study tested the drug durvalumab (Imfinzi) combined with two different schedules of stereotactic radiation for people with advanced non-small cell lung cancer. The goal was to see if the combination improved quality of life and controlled tumor growth. However, the t…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Promising combo for rare lymphoma hits roadblock: trial ends early
Disease control TerminatedThis study tested a combination of two drugs, ixazomib and romidepsin, for people with a rare type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to treatment. The trial was stopped early after enrolling only 11 participants, so the high…
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail aims to keep multiple myeloma in check
Disease control TerminatedThis study looked at whether adding the drug ixazomib to lenalidomide and dexamethasone can help people with multiple myeloma stay in remission longer after their first round of chemotherapy. About 141 adults who had already completed 3 cycles of a bortezomib-based regimen took p…
Phase: PHASE4 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Glow-in-the-dark dye could help surgeons save tiny glands during thyroid surgery
Disease control TerminatedThis study tested whether a fluorescent dye called indocyanine green can help surgeons find and protect the parathyroid glands during thyroid or parathyroid surgery. The dye is injected into the bloodstream and makes the glands glow under a special camera. The trial enrolled 417 …
Phase: PHASE4 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug tested for Post-Transplant blood cancers — but study halted early
Disease control TerminatedThis pilot study tested the drug ADCT-301 in 3 adults whose acute myeloid leukemia, myelodysplastic syndrome, or related blood cancer had returned after a stem cell transplant. The goal was to see if the drug could safely bring about remission. However, the study was terminated e…
Phase: PHASE2 • Sponsor: Gwynn Long, M.D. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Cancer combo trial halted early: what we learned
Disease control TerminatedThis study tested a combination of two drugs, donafenib and KN046, in people with advanced gastrointestinal cancers that had not responded to standard treatments. The goal was to check safety and see if the drugs could shrink tumors. The trial was stopped early, and only 15 peopl…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental triple therapy for advanced cancers shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested the drug plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could shrink…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New pill aims to tame ulcerative colitis Flare-Ups
Disease control TerminatedThis study tested an experimental daily tablet called VTX002 in people with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. About 213 participants were randomly assigned to receive one of two doses of VTX002 or a placebo for 13 weeks, with the option …
Phase: PHASE2 • Sponsor: Oppilan Pharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo aims to control resistant liver cancer
Disease control TerminatedThis study tested whether adding an experimental drug (VIC-1911) to the standard drug lenvatinib could help people with liver cancer that no longer responds to lenvatinib alone. Only 5 people were enrolled before the study was stopped early. The goal was to see if the combination…
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Experimental immune cell therapy for advanced cancers shows early safety data
Disease control TerminatedThis early-phase study tested a personalized cell therapy made from a patient's own tumor-fighting immune cells. It aimed to see if the treatment was safe for people with advanced solid tumors that had spread or come back. Only 2 people took part before the study was stopped earl…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Lung cancer immune cell therapy study stopped early after just 2 patients
Disease control TerminatedThis study tested a treatment called GT201, which uses immune cells taken from a patient's own tumor to attack advanced lung cancer. It was designed for adults aged 18-70 with non-small cell or small cell lung cancer that had stopped responding to standard treatments. The study w…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental TIL therapy for advanced gynecological tumors shows early promise but study halted
Disease control TerminatedThis early study tested a new treatment called GT201 for people with advanced gynecological tumors, like advanced cervical cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight the cancer. The study was terminated early after enrolling …
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Lung cancer drug combo trial halted early
Disease control TerminatedThis study tested a new combination of cancer drugs (bemarituzumab plus anlotinib) against a standard treatment (tislelizumab) for people with extensive-stage small cell lung cancer. The goal was to see if the new combo could delay cancer growth or improve survival. However, the …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental immune cell therapy targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or returned. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are collected from a tumor, multiplied in a lab, and then inf…
Phase: PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental TIL therapy tested in one patient for advanced gynecological tumors
Disease control TerminatedThis early-phase study tested an experimental cell therapy called GT201, made from a patient's own immune cells, for advanced gynecological tumors. Only one person took part before the study was stopped early. The goal was to check safety and see if the treatment could shrink tum…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental immune cell therapy for advanced cancers shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested a personalized therapy called GT201, made from a patient's own tumor-fighting immune cells (TILs), for advanced solid tumors. Only 6 people were enrolled before the study was terminated. The treatment involved intensive chemotherapy followed by infus…
Phase: PHASE1, PHASE2 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Lung cancer immune cell trial halted after just 2 patients
Disease control TerminatedThis early trial tested a treatment that takes immune cells from a patient's own tumor, grows them in a lab, and gives them back along with an immune-boosting drug called teraplizumab. The goal was to see if this combination is safe and tolerable for people with advanced non-smal…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Liver cancer drug trial halted after just 3 patients
Disease control TerminatedThis study tested the drug lenvatinib in people whose liver cancer came back after a liver transplant. The goal was to see if the drug could shrink tumors. Only 3 people joined before the study was stopped early, so we have very limited information on how well it works.
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug NB004 tested in Early-Stage trial
Disease control TerminatedThis early-stage study tested a new drug called NB004 in 25 adults with advanced solid tumors that had no standard treatment options. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Ningbo Newbay Technology Development Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-stage study tested an experimental oral drug called M1069 in 15 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so results are limited and…
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Bladder cancer radiation trial halted early – only 2 patients enrolled
Disease control TerminatedThis study tested a new type of radiation therapy that adapts daily to the patient's anatomy, combined with chemotherapy, for muscle-invasive bladder cancer. The goal was to see if this approach could lower severe bowel and bladder side effects compared to standard radiation. How…
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Radiation boosts immunotherapy in melanoma? small trial halted early
Disease control TerminatedThis phase II trial tested whether adding radiotherapy to the immunotherapy drug pembrolizumab could better control advanced melanoma than pembrolizumab alone. Only 17 people took part before the study was stopped early. The goal was to see if radiation could trigger an 'abscopal…
Phase: PHASE2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Melanoma drug combo study halted before full results
Disease control TerminatedThis study tested a combination of two drugs, ipilimumab and epacadostat, in people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if adding epacadostat to standard treatment improved survival. However, the study was stopped early f…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental combo for resistant breast cancer shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested a combination of two oral drugs, BKM120 and lapatinib, in 24 people with HER2-positive breast cancer that had stopped responding to trastuzumab. The goal was to find a safe dose and see if the combination could shrink tumors. The study was terminated…
Phase: PHASE1, PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Lung cancer combo trial halted early – too few patients to draw conclusions
Disease control TerminatedThis phase 2 study tested whether adding itacitinib to standard chemotherapy (docetaxel) could help people with advanced non-small cell lung cancer live longer. The trial was stopped early after enrolling only 9 participants, so we cannot tell if the combination is safe or effect…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising myeloma combo trial halted after just 4 patients
Disease control TerminatedThis very early study tested two drugs, alnuctamab and mezigdomide, together in people with multiple myeloma that had come back or stopped responding to treatment. The goal was to find a safe dose and see if the combination could shrink tumors. However, the trial was stopped earl…
Phase: PHASE1 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Common diabetes and acne drugs tested against cancer
Disease control TerminatedThis phase 2 trial tested whether combining metformin (a diabetes drug) with doxycycline (an antibiotic) could help treat localized breast and uterine cancers. The study enrolled 29 people who were scheduled for surgery. Researchers looked at changes in certain proteins in the tu…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising combo for Hard-to-Treat breast cancer hits snag, trial halted
Disease control TerminatedThis study tested a new drug (LY2780301) combined with standard chemotherapy (paclitaxel) in people with advanced HER2-negative breast cancer that had spread or couldn't be removed by surgery. The goal was to find the safest dose and see if the combination could shrink tumors. Th…
Phase: PHASE1, PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Triple-Drug attack on tough leukemia shows promise but trial halted
Disease control TerminatedThis early-phase trial tested a combination of three drugs—magrolimab, azacitidine, and venetoclax—in 110 adults with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find the best dose and see if the combination could put the cancer into r…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising combo for prostate cancer halted early
Disease control TerminatedThis study looked at adding ribociclib to the standard hormone therapy enzalutamide for men with a certain type of advanced prostate cancer that had spread and no longer responded to hormone therapy alone. The goal was to find the best dose and see if the combination could lower …
Phase: PHASE1, PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can vitamin d tweak breast cancer genes? weight may matter
Disease control TerminatedThis study looked at whether taking vitamin D could change certain genes in breast cancer tumors, and if a woman's weight affected those changes. Researchers gave 41 women with breast cancer either a low or high dose of vitamin D before surgery. The goal was to see if vitamin D c…
Phase: PHASE2 • Sponsor: Melinda Telli • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental cell therapy for advanced lung cancer shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a personalized treatment called GTE-001, which uses immune cells taken from a patient's own tumor to attack their cancer. It was designed for people with advanced lung adenocarcinoma that had stopped responding to standard chemotherapy. However, the …
Phase: PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental combo for tough cancers shows early promise, but trial halted
Disease control TerminatedThis early-phase study tested a combination of two drugs—atezolizumab (an immunotherapy) and epacadostat (an oral drug that helps the immune system attack cancer)—in 29 patients with advanced lung or bladder cancer that had already been treated with chemotherapy. The main goal wa…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Experimental cancer drug AUR106 tested in humans for first time
Disease control TerminatedThis early-stage trial tested an experimental drug called AUR106 in 21 adults with advanced solid tumors (lung, stomach, bladder, kidney, colon, or esophageal cancer) that had come back or spread. The main goals were to check safety, find the right dose, and see how the drug move…
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New cancer drug AUR109 tested in three tumor types – trial halted early
Disease control TerminatedThis phase 2 study tested three doses of the experimental drug AUR109 in 29 adults with advanced colorectal, ovarian, or kidney cancer who had already tried at least two other treatments. The goal was to see if the drug could shrink tumors and to check its safety. The trial was t…
Phase: PHASE2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Early lung cancer drug combo trial halted after just 6 patients
Disease control TerminatedThis study looked at giving the immunotherapy drug pembrolizumab (Keytruda) alone or with chemotherapy before surgery for people with early-stage non-small cell lung cancer. The goal was to see if these treatments could shrink tumors and improve outcomes. However, the trial was s…
Phase: PHASE2 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New cancer pill tested in humans – but trial halted early
Disease control TerminatedThis early-stage trial tested an oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had not responded to prior treatments. The study aimed to find a safe dose and check how the drug moves through the body. However, the trial was terminated, so resul…
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Promising combo for stomach cancer stalls: trial ends early
Disease control TerminatedThis early-stage trial tested a new drug called AUR103 calcium, given together with standard treatments (trastuzumab and chemotherapy), for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The study aimed to find a safe dose and check if the combina…
Phase: PHASE1, PHASE2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Chemo patch for skin cancer shows promise in early trial
Disease control TerminatedThis early-stage study tested a new way to deliver the chemotherapy drug doxorubicin directly into basal cell skin cancer using tiny dissolving needles on a patch. The goal was to find a safe dose and see if it could completely remove the cancer. The study included 13 adults with…
Phase: PHASE1 • Sponsor: SkinJect, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New radiation technique tested for aggressive brain cancer
Disease control TerminatedThis phase 3 trial tested two types of radiation therapy for glioblastoma, a fast-growing brain tumor. One group received standard 3D radiation, while the other got a more precise intensity-modulated radiation guided by MRI scans. Both groups also took the chemotherapy drug temoz…
Phase: PHASE3 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Pazopanib dose hunt in frail seniors halted early
Disease control TerminatedThis phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…
Phase: PHASE1 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Stem cell shot for Crohn's pouch fistulas shows early promise but study halted
Disease control TerminatedThis early-phase study tested whether injecting stem cells from donor bone marrow could safely heal fistulas (abnormal tunnels) in people with Crohn's disease who have a J-pouch after colon removal. The study aimed to see if the treatment could close the fistulas and improve symp…
Phase: PHASE1, PHASE2 • Sponsor: Anthony Lembo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental immune cell therapy targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…
Phase: PHASE1 • Sponsor: Instil Bio • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental lymphoma drug IPH6501 tested in early trial – but study halted
Disease control TerminatedThis early-phase trial tested an experimental drug called IPH6501 in 23 people with certain types of Non-Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to check safety and find the right dose, while also looking for signs that the drug …
Phase: PHASE1, PHASE2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Cancer Patients' chest fluid: can a Clot-Buster help drain it?
Disease control TerminatedThis study tested whether a drug called TNK (tenecteplase) could help drain loculated (pocketed) fluid from the chest in cancer patients better than a saltwater solution. The trial planned to enroll about 20 adults with cancer and a chest tube already in place. However, the study…
Phase: PHASE2, PHASE3 • Sponsor: Kaiser Permanente • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental drug tested for rare cancer, trial stopped early
Disease control TerminatedThis study tested a drug called XmAb23104 in people with advanced sarcoma, a rare cancer. The goal was to see if the drug could shrink tumors and if it was safe. Only 6 people took part before the study was ended early.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Lung cancer radiation trial halted early – only 6 patients enrolled
Disease control TerminatedThis early-phase trial tested whether giving a higher radiation dose directly to the lung tumor (while keeping standard doses to surrounding areas) is safe for people with non-small cell lung cancer. Only 6 participants were enrolled before the study was terminated. The goal was …
Phase: PHASE1, PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail shows promise in tough lung cancers
Disease control TerminatedThis study tested a new drug called TQB3616 combined with either anlotinib or standard chemotherapy in 21 people with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or slow the cancer's growth. The study was stopped …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo tackles pancreatic cancer resistance – but study halted early
Disease control TerminatedThis study tested whether combining two drugs, trametinib and hydroxychloroquine, could help overcome treatment resistance in people with advanced pancreatic cancer that had spread. The trial aimed to see how many patients were free of cancer growth after 12 weeks. It included 20…
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Promising prostate cancer combo trial stalls after just 7 patients
Disease control TerminatedThis phase II trial tested two drugs—denosumab and enzalutamide—together in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal was to see if the combination could slow cancer growth better than enzalutamide alone. Ho…
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Breast cancer radiation showdown: 3D vs internal implants
Disease control TerminatedThis study compared two types of radiation given after breast-conserving surgery for early-stage breast cancer: 3D conformal radiation (external beams) and internal brachytherapy (radioactive material placed in the breast). Only 6 women took part before the trial was stopped earl…
Phase: NA • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental cancer drug BAT8007 tested in early trial – but study halted
Disease control TerminatedThis early-phase trial tested a new drug called BAT8007 in 93 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target a protein called Nectin-4 on cancer cells and deliver a chemotherapy agent directly to them. The main…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New antibody drug tested in patients with advanced stomach and gut cancers
Disease control TerminatedThis early-stage study tested a new drug called DR30303 in 13 people with advanced digestive system cancers that had stopped responding to standard treatments. The drug is a lab-made antibody designed to target a protein called CLDN18.2 found on some cancer cells. The main goals …
Phase: PHASE1 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail tested for ovarian cancer maintenance
Disease control TerminatedThis study looked at whether adding a third drug (fluzoparib) to a two-drug combination (apatinib and letrozole) could help control recurrent ovarian cancer longer. It included people with a specific type of ovarian cancer that had come back but still responded to platinum chemot…
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental lymphoma drug CPO107 tested in small early trial
Disease control TerminatedThis early study tested a new drug called CPO107 in 7 people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find a safe dose and see how the body handles the drug. The trial was stopped early, so we have limited informati…
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental drug gentulizumab tested for tough blood cancers – but trial halted early
Disease control TerminatedThis early-stage trial tested a new drug called gentulizumab in 58 people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had come back or stopped responding to treatment. Gentulizumab is an antibody that helps the immune system attack cancer cells. The m…
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Lung cancer drug trial halted: olaparib shows no clear benefit in maintenance therapy
Disease control TerminatedThis study tested whether the drug olaparib could help keep advanced non-small cell lung cancer from growing after initial chemotherapy. Only patients whose cancer responded to platinum-based chemotherapy were eligible. The trial was terminated early, meaning it did not show enou…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Cold plasma zaps away Kids' skin lesions in new trial
Disease control TerminatedThis study tested a cold atmospheric plasma device on children aged 4-21 with warts or molluscum lesions. The device uses ionized gas to treat the lesions without heat. The trial was terminated early, so we don't have full results on how well it worked or its safety.
Phase: PHASE3 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental lung cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called TRX-221 in people with a specific type of advanced lung cancer (EGFR mutant NSCLC) that had stopped responding to standard treatments. The goal was to see if the drug was safe and could shrink tumors. The trial was stopped early, and only 19 pe…
Phase: PHASE1, PHASE2 • Sponsor: Therapex Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Promising prostate cancer combo study halted early
Disease control TerminatedThis study tested whether adding the drug SHR3680 to standard hormone therapy could improve outcomes for men with high-risk prostate cancer before they had surgery to remove the prostate. The trial enrolled 391 participants and aimed to see if the combination could eliminate all …
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental lung cancer drug trial halted early – only 18 patients enrolled
Disease control TerminatedThis early-stage trial tested a new drug, TAS3351, in 18 people with advanced lung cancer that had a specific genetic change (EGFR mutation). The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Stem cell transplant study halted early: which prep works best?
Disease control TerminatedThis study tested two different drug combinations given before a stem cell transplant for people with myeloid blood cancers like leukemia. One group got fludarabine and busulfan, the other got those drugs plus low-dose total body irradiation. The goal was to see which regimen led…
Phase: PHASE3 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental cancer drug CPO-100 trial halted early
Disease control TerminatedThis early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental combo for tough lymphoma shows early promise, but trial halted
Disease control TerminatedThis early-stage trial tested a combination of two oral drugs, tazemetostat and venetoclax, in people with non-Hodgkin lymphoma that had come back or stopped responding to treatment. Only 3 people enrolled before the study was terminated. The main goals were to find the safest do…
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Immunotherapy combo after transplant shows promise for High-Risk blood cancers
Disease control TerminatedThis study tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) after a stem cell transplant could safely help control high-risk multiple myeloma and lymphoma. It involved 46 adults aged 18-80 whose cancer was at high risk of coming back. The main goal was to …
Phase: PHASE1, PHASE2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Hormone blocker added to chemo for bladder cancer: early study halted
Disease control TerminatedThis early study tested adding a testosterone-lowering drug (degarelix) to standard chemotherapy for people with muscle-invasive bladder cancer that has testosterone receptors. Only 2 people enrolled before the study was stopped. The goal was to see if the combination could elimi…
Phase: PHASE1 • Sponsor: Brown University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Cancer drug lenalidomide tested for HIV-Linked kaposi sarcoma
Disease control TerminatedThis phase 2 trial tested the drug lenalidomide in 12 people with HIV who had Kaposi sarcoma, a type of cancer. Participants took lenalidomide pills for 21 days each month. The study aimed to see if the drug could shrink tumors, but it was stopped early, so the results are not co…
Phase: PHASE2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental chemo cocktail targets resistant leukemia
Disease control TerminatedThis study tested a combination of chemotherapy drugs (cladribine, cytarabine, mitoxantrone, and G-CSF) in 53 adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that had come back or not responded to prior treatment. The goal was to see how many …
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Leukemia drug spectrila tested in adults: phase 2 trial looks at drug levels and safety
Disease control TerminatedThis study tested the drug Spectrila (a form of L-asparaginase) in 40 adults aged 18-55 with newly diagnosed B-cell acute lymphoblastic leukemia. The goal was to see if the drug reached effective levels in the blood and to check its safety and immune response. The trial was termi…
Phase: PHASE2 • Sponsor: medac GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug OMS721 tested for rare kidney conditions
Disease control TerminatedThis study tested a drug called OMS721 in 31 people with certain kidney diseases, including IgA nephropathy and lupus nephritis. The main goal was to check if the drug is safe and if it reduces protein in the urine, a sign of kidney damage. The study was stopped early, so results…
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental drug combo for head and neck cancer shows early promise
Disease control TerminatedThis early-stage trial tested an experimental drug called xevinapant combined with standard chemotherapy and radiation in people with head and neck cancer who cannot take the usual drug cisplatin. The goal was to find the safest dose of xevinapant. The study was terminated early,…
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental INKmune therapy for blood cancers halted after just 2 patients
Disease control TerminatedThis early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no c…
Phase: PHASE1 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Chemo cocktail aimed at zapping pancreatic cysts
Disease control TerminatedThis study tested whether injecting chemotherapy drugs directly into pancreatic cysts could shrink or eliminate them. It involved 75 adults with cysts between 2-5 cm. The approach used an endoscope to guide the injection, comparing two different pre-treatment rinses. The trial wa…
Phase: PHASE3 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental prostate cancer pill put to the test
Disease control TerminatedThis early-stage study tested a new drug called TQB3720 in 192 men with advanced prostate cancer that had stopped responding to hormone therapy. The main goal was to find a safe dose and see how the drug moves through the body. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising combo trial for lymphoma halted early
Disease control TerminatedThis early-stage trial tested a combination of two immune-boosting drugs—pembrolizumab (Keytruda) and CMP-001—in 14 adults with lymphomas that had come back or stopped responding to treatment. The goal was to find a safe dose that could shrink tumors. However, the study was termi…
Phase: PHASE1, PHASE2 • Sponsor: Umar Farooq • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising combo for brain metastases? trial ends early
Disease control TerminatedThis early-phase trial tested two oral drugs, abemaciclib and elacestrant, in women with a type of breast cancer (HR+/HER2-) that had spread to the brain. The goal was to see if the combination was safe and could shrink brain tumors. However, the study was stopped early after enr…
Phase: PHASE1, PHASE2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Cell sheet trial for esophageal cancer patients ends early with just one volunteer
Disease control TerminatedThis study tested a treatment using a sheet of the patient's own mouth cells to prevent the esophagus from narrowing after cancer removal surgery. Only one person took part before the study was stopped early. The goal was to see if the cell sheet could safely reduce scarring and …
Phase: PHASE3 • Sponsor: CellSeed Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental cancer combo shows early promise but study halted
Disease control TerminatedThis early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…
Phase: PHASE1 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Immunotherapy combo shows promise for advanced cervical cancer
Disease control TerminatedThis phase 2 trial tested two immunotherapy drugs, AGEN2034 and AGEN1884, in 211 women with recurrent cervical cancer that had progressed after chemotherapy. One group received AGEN2034 alone, the other received both drugs. The goal was to see if the tumors shrank. The study was …
Phase: PHASE2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Radiation plus immunotherapy: new hope for head and neck cancer?
Disease control TerminatedThis phase 2 trial tested whether adding radiotherapy to the immunotherapy drug pembrolizumab (Keytruda) helps shrink tumors in people with metastatic head and neck cancer that has spread. The study planned to enroll 115 participants, but was terminated early. Researchers measure…
Phase: PHASE2 • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental lung cancer vaccine trial halted early
Disease control TerminatedThis early-stage trial tested an experimental immunotherapy called IMU-201 (PD1-Vaxx) in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or combined with another immunotherapy drug (atezolizumab) and sometimes chemotherapy. The goal was to check …
Phase: PHASE1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental combo therapy for brain cancer shows promise in early trial
Disease control TerminatedThis study tested a special type of radiation (pulse reduced dose rate) combined with the drug bevacizumab in 49 people with recurrent high-grade gliomas (brain tumors). The goal was to see if this combination could help patients live longer. Participants received radiation over …
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New gel aims to stop deadly leaks after bowel surgery
Disease control TerminatedThis study tested a new gel called Dehisgel in 20 adults who had colorectal surgery for rectal cancer. The goal was to see if the gel could safely prevent leaks where the bowel was reconnected. The study was stopped early, so results are limited.
Sponsor: Contipro Pharma a.s. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental combo targets lung cancer that resists immunotherapy
Disease control TerminatedThis early-stage trial tested a combination of two treatments—atezolizumab (an immunotherapy drug) and interleukin-12 gene therapy (which uses a virus to deliver a gene that boosts the immune system)—in 13 people with advanced non-small cell lung cancer that had worsened after in…
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental combo targets deadly thyroid cancer
Disease control TerminatedThis phase 2 trial tested whether the immunotherapy drug pembrolizumab, given after radiation therapy, could help control anaplastic thyroid cancer that is still in the neck. Only 6 patients were enrolled before the study was stopped early. The goal was to see how long patients l…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Radioactive microparticles injected into pancreatic tumors: a new hope?
Disease control TerminatedThis study aimed to see if injecting radioactive particles (OncoSil) directly into pancreatic tumors during an endoscopic ultrasound, combined with chemotherapy, could safely shrink tumors and improve survival. It was designed for people with advanced pancreatic cancer that could…
Phase: PHASE2, PHASE3 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Pfizer tests new drug combo for advanced cancers – but study ends early
Disease control TerminatedThis early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy-Chemo cocktail tested for head and neck cancer – early trial stopped
Disease control TerminatedThis early-phase trial tested whether adding the immunotherapy drug durvalumab to standard chemotherapy (docetaxel, cisplatin, and 5-FU) is safe for people with advanced head and neck cancer. Only 14 patients were enrolled before the study was stopped. The goal was to find the ri…
Phase: PHASE1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental drug for tough leukemias hits dead end
Disease control TerminatedThis early-phase trial tested an oral drug called NMS-03592088 in 63 adults with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML) that had come back or not responded to standard treatments. The goal was to check safety, find the right dose, and see if it cou…
Phase: PHASE1, PHASE2 • Sponsor: Nerviano Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental drug voruciclib tested in desperate blood cancer patients
Disease control TerminatedThis early-phase trial tested an experimental drug called voruciclib, either alone or combined with another drug (venetoclax), in adults with several types of blood cancers (like lymphoma, leukemia) that had come back or stopped responding to prior treatments. The main goal was t…
Phase: PHASE1 • Sponsor: MEI Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New chemo combo after radiation shows promise for advanced cervical cancer
Disease control TerminatedThis study looked at whether adding a specific chemotherapy combination (carboplatin and paclitaxel) after standard chemoradiation could help people with advanced cervical cancer that has spread to lymph nodes near the kidneys. The trial planned to enroll 21 participants but was …
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
CAR-T trial for blood cancer halted after single patient
Disease control TerminatedThis study tested a new CAR-T cell therapy for people with multiple myeloma that had come back or stopped responding to treatment. The therapy uses a patient's own immune cells to target cancer cells. The trial was stopped early and only enrolled one person, so we have very limit…
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo targets brain metastases in advanced cancers
Disease control TerminatedThis study tested a combination of two drugs, bintrafusp alfa and pimasertib, in people whose cancer had spread to the brain. The goal was to find the safest dose and see if the treatment could slow or stop the cancer from growing. The trial was stopped early after enrolling only…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo for kidney cancer shows promise but trial halted early
Disease control TerminatedThis phase 3 study tested whether adding atezolizumab (an immunotherapy) to cabozantinib (a targeted therapy) helps people with advanced kidney cancer whose disease worsened after prior immunotherapy. The trial enrolled 522 participants but was terminated early, so the full benef…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Experimental combo for MDS and AML shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested an experimental drug called SL-172154, given alongside standard chemotherapy drugs, for people with higher-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goals were to check safety and find the right dose. The study was…
Phase: PHASE1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Experimental CAR T-Cell therapy targets tough lymphoma
Disease control TerminatedThis early-phase trial tested a new treatment called AUTO4 for people with a type of T-cell lymphoma that had come back or not responded to prior therapy. AUTO4 is a CAR T-cell therapy designed to recognize and attack cancer cells carrying a specific marker called TRBC1. The stud…
Phase: PHASE1, PHASE2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Cord blood immune cells tested against tough leukemia
Disease control TerminatedThis early-phase trial tested a new treatment for adults with acute myeloid leukemia that had come back or not responded to standard therapy. The treatment involved giving patients natural killer cells grown from donated umbilical cord blood, along with a drug called IL-2 to help…
Phase: PHASE1, PHASE2 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental lung cancer drug trial halted early
Disease control TerminatedThis early-stage trial tested a new immunotherapy drug called vudalimab combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It compared this combination to the standard treatment of pembrolizumab plus chemotherapy. The study was terminated ear…
Phase: PHASE1, PHASE2 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control TerminatedThis study tested a new experimental drug, BGB-A3055, alone or with another drug (tislelizumab), in people with advanced or metastatic solid tumors. The goal was to check safety, how the body handles the drug, and any early signs of tumor shrinkage. The study was stopped early, b…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental lymphoma therapy tested in tiny early trial
Disease control TerminatedThis phase 1 trial tested a two-step radioimmunotherapy (CD38-SADA and 177Lu-DOTA) in patients with relapsed or refractory non-Hodgkin lymphoma. The goal was to find safe doses and dosing schedules. Only 1 participant was enrolled, and the study was terminated early, so no conclu…
Phase: PHASE1 • Sponsor: Y-mAbs Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Lung cancer immunotherapy cocktail shows promise but trial halted early
Disease control TerminatedThis phase 2 trial tested two immunotherapy drugs (tiragolumab and atezolizumab) with or without chemotherapy in 50 people with early-stage non-small cell lung cancer that could be surgically removed. The goal was to see if the treatment shrank tumors before surgery and prevented…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising combo for cervical cancer hits roadblock: trial ends early
Disease control TerminatedThis phase 2 trial tested a new treatment sequence for stage IB2 to IVA cervical cancer. Patients received a combination of gemcitabine and cisplatin chemotherapy along with radiation, followed by more gemcitabine. The goal was to see if this approach could improve progression-fr…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Cancer drug imatinib tested for rare eye melanoma – but trial stops early
Disease control TerminatedThis phase II trial tested the drug imatinib in 13 adults with metastatic ocular melanoma, a rare eye cancer that has spread. The goal was to see if imatinib could stop tumor growth for at least 3 months. The trial was terminated early, so the results are limited and it is unclea…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental donor CAR-T therapy tested in lymphoma – trial halted early
Disease control TerminatedThis early-phase trial tested a new therapy called ATA3219, which uses immune cells from a healthy donor to attack cancer cells in people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aimed to check safety and see if the treatment works, but it was stopped ea…
Phase: PHASE1 • Sponsor: Atara Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo for cervical cancer shows early promise, but trial halted
Disease control TerminatedThis early-phase trial tested a combination of two drugs—toripalimab (an immunotherapy) and chidamide (a targeted therapy)—in women with advanced cervical cancer that had spread or returned. Only 5 participants were enrolled before the study was terminated. The goal was to see if…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising combo for prostate cancer falls short: trial ends early
Disease control TerminatedThis study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with advanced prostate cancer that no longer responds to hormone therapy alone. The goal was to see if the combination could slow cancer growth bet…
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Liver cancer drug combo put to the test – but trial stops early
Disease control TerminatedThis phase 3 trial compared a combination of two drugs (regorafenib and pembrolizumab) with standard locoregional therapies (TACE or TARE) as a first treatment for intermediate-stage liver cancer that has spread beyond certain limits. The study aimed to enroll about 496 people bu…
Phase: PHASE3 • Sponsor: Translational Research in Oncology • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental CAR T-Cell therapy targets rare B-Cell cancers
Disease control TerminatedThis phase 2 study tested a treatment called brexucabtagene autoleucel, a CAR T-cell therapy made from a patient's own immune cells, for four rare B-cell cancers: Waldenstrom macroglobulinemia, Richter transformation, Burkitt lymphoma, and hairy cell leukemia. The trial enrolled …
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising breast cancer combo trial shutters after just one patient
Disease control TerminatedThis phase 2 trial aimed to see if adding the targeted drug binimetinib to the standard hormone therapy fulvestrant could help people with a certain genetic change (NF1) in hormone receptor-positive breast cancer that has spread. Only one person enrolled before the study was term…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental lymphoma drug ASTX660 tested in tiny, terminated trial
Disease control TerminatedThis early-phase trial tested the drug ASTX660 in just 8 people with T-cell lymphoma that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for side effects, but it was stopped early. Because it was so small and incomplete, we cannot…
Phase: PHASE1, PHASE2 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
A radioactive clue that could spare thousands from thyroid surgery
Diagnosis TerminatedThis trial tests whether a special imaging scan using a small amount of radioactive iodine (iodine-123) can tell the difference between benign and cancerous thyroid nodules before surgery. Currently, biopsy alone can't always make that call, so many people undergo surgery just to…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
Can a simple test spot heart damage in cancer survivors?
Diagnosis TerminatedThis study looks at whether a special ECG and a blood test can find early signs of heart weakness in adult cancer survivors who had certain chemotherapy. Researchers will check how well these tests work compared to standard heart imaging. The goal is to gather information needed …
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
A simple breath test could spot mesothelioma years earlier
Diagnosis TerminatedThis study explores whether chemicals in a person's breath, called volatile organic compounds, can serve as early warning signs of pleural mesothelioma in people who have been exposed to asbestos. Researchers will also check if a blood marker, SMRP, adds to the breath test's accu…
Sponsor: Henry Ford Health System • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
New PET scan could help doctors choose the right chemo for cancer patients
Diagnosis TerminatedThis early-phase trial is testing whether a new radioactive tracer called 18F-Clofarabine (CFA) can be used in PET scans to measure an enzyme activity in cancer cells that may predict how well certain drugs like gemcitabine work. Four adults with metastatic cancer will receive th…
Phase: EARLY_PHASE1 • Sponsor: Roberto Vargas • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
AI reads scans to spot esophageal cancer and predicts best treatment path
Diagnosis TerminatedThis study tests two AI models that analyze endoscopy and CT images to diagnose esophageal cancer and predict how deep the tumor has grown. The goal is to help doctors decide if a patient can be treated with a less invasive endoscopic procedure or needs more aggressive therapy. T…
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Aug 07, 2026 00:00 UTC
-
Can an ultrasound predict who can skip surgery for rectal cancer?
Diagnosis TerminatedThis study tested whether a special ultrasound technique (D-CEUS) can predict how well rectal cancer responds to chemotherapy and radiation. The goal is to identify good responders who might avoid major surgery and instead have a less invasive procedure. Only 2 people took part, …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Aug 01, 2026 00:00 UTC
-
Metabolic MRI could spot prostate cancer without a needle
Diagnosis TerminatedThis study tests a new type of MRI scan that uses a special contrast agent called hyperpolarized pyruvate to see how prostate cells use energy. The goal is to safely distinguish cancerous from normal tissue in men with suspected or known prostate cancer. Participants receive the …
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
New blood test aims to catch live prostate cancer cells
Diagnosis TerminatedThis study tests a new blood test called EPIDROP that looks for live circulating tumor cells in men with metastatic prostate cancer. The test uses a special technique to isolate single cells and measure their activity. Researchers want to see if EPIDROP is as good as or better th…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Super-Fine ultrasound could spare melanoma patients a second surgery
Diagnosis TerminatedThis trial investigates whether a new, ultra-high-frequency ultrasound device can accurately measure the depth of skin melanomas before surgery. Currently, doctors must remove the tumor, measure its depth under a microscope, and then often perform a second surgery to remove more …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Triple imaging technique aims to sharpen prostate cancer detection
Diagnosis TerminatedThis study tested a new way to guide prostate biopsies by combining three imaging methods: a PET scan using a special tracer (fluorocholine), multiparametric MRI, and 3D ultrasound. The goal was to see if this triple approach could more accurately target suspicious areas in the p…
Phase: NA • Sponsor: Lille Catholic University • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New scan could predict hormone therapy success in breast cancer
Diagnosis TerminatedThis study tested a special PET/CT scan using a radioactive tracer called FES to see estrogen receptor activity in women with advanced, hormone-resistant breast cancer. The goal was to see if the scan could predict how well a new hormone therapy would work. Only 6 people were enr…
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Fewer biopsy cores may be safer and just as accurate for prostate cancer detection
Diagnosis TerminatedThis study looked at whether taking fewer systematic biopsy cores (6 instead of 20) during an MRI-targeted prostate biopsy could still detect dangerous prostate cancers while reducing risks like infection and overdiagnosis. The trial involved 126 men with suspicious MRI results. …
Phase: NA • Sponsor: IRCCS San Raffaele • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Pee test could replace pap smear for some women
Diagnosis TerminatedThis study tested whether offering a home urine test for human papillomavirus (HPV) could encourage more women to get screened for cervical cancer. The trial targeted women aged 30–65 in Brittany, France, who had not responded to an initial invitation for a Pap smear. Participant…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
New PET tracer aims to light up tumors, but trial stalls
Diagnosis TerminatedThis early-phase trial tested a radioactive imaging agent called 68GaNOTA-Anti-MMR-VHH2 to see if it could safely highlight tumors on PET scans. It involved 13 adults with advanced solid tumors, breast cancer, or melanoma. The study was terminated early, so we have limited inform…
Phase: PHASE1, PHASE2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
New PET tracer could spot hidden brain tumors in cancer patients
Diagnosis TerminatedThis study tested a special radioactive tracer (68GaNOTA-Anti-HER2 VHH1) to see if it can find HER2-positive brain metastases on PET/CT scans. Seven adult cancer patients with at least one brain lesion were enrolled. The goal was to compare tracer uptake in HER2-positive versus H…
Phase: PHASE2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New PET tracer aims to reveal hidden immune activity in tumors and arteries
Diagnosis TerminatedThis Phase II study tested a radioactive tracer called 68GaNOTA-Anti-MMR-VHH2 to see if it can light up certain immune cells (macrophages) on PET scans. The trial included 29 people with head and neck cancer, lymphoma, atherosclerosis, or sarcoidosis. The goal was to see if the t…
Phase: PHASE2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New screening method aims to catch lung cancer earlier in asbestos workers
Diagnosis TerminatedThis study looked at whether analyzing sputum (phlegm) with automated cytometry, combined with low-dose CT scans and blood tests, could better detect lung cancer in workers heavily exposed to asbestos. The goal was to reduce false positives and improve early diagnosis. The trial …
Phase: PHASE3 • Sponsor: University Hospital, Caen • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New scan could sharpen ovarian cancer detection
Diagnosis TerminatedThis study tested whether a new radioactive tracer called FAPI-46, used with a PET/CT scan, can more accurately detect the spread of ovarian cancer compared to standard scans. Researchers planned to enroll 50 women with newly diagnosed ovarian cancer, but the study was terminated…
Phase: PHASE2 • Sponsor: Aalborg University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
New PET scan agent aims to map hidden prostate cancer spread
Diagnosis TerminatedThis study tested a new imaging agent called 68Ga-PSMA-11 to see if it could give clearer pictures of where prostate cancer has spread in men with advanced, treatment-resistant disease. The goal was to help doctors better understand the location of tumors. The study was terminate…
Phase: PHASE2 • Sponsor: Thomas Hope • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Blood RNA may reveal hidden liver cancers
Diagnosis TerminatedThis study looked at whether tiny bits of RNA in the blood can serve as markers for liver disease and liver cancer. Researchers collected blood samples from nearly 1,900 people with liver cancer, cirrhosis, or chronic liver disease. The goal was to see if these RNA markers could …
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New MRI dye could spot hidden prostate cancer cells
Diagnosis TerminatedThis phase 3 trial tested whether an iron-based contrast agent called Ferumoxtran-10 (Ferrotran®) could improve MRI scans to find prostate cancer that has spread to lymph nodes. The study involved 172 men with newly diagnosed prostate cancer at intermediate to high risk of spread…
Phase: PHASE3 • Sponsor: Saving Patients' Lives Medical B.V. • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Shorter, cheaper liver scans for cancer patients? small study tests new approach
Diagnosis TerminatedThis study compared two different contrast agents used in liver MRI scans to see if a shorter, cheaper scan could work as well as the standard one for finding colorectal cancer that has spread to the liver. The trial planned to enroll 10 adults with suspected liver metastases, bu…
Phase: PHASE4 • Sponsor: University of Colorado, Denver • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New blood test aims to cut unnecessary colonoscopies after cancer screen
Diagnosis TerminatedThis pilot study tested a blood-based test (Harbinger test) to help decide who needs a colonoscopy after a positive colorectal cancer screening. The goal was to see if the blood test could accurately predict colorectal cancer or advanced adenomas. However, the study was terminate…
Sponsor: Harbinger Health • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Tablet app tracks eye movements to spot chemo brain
Diagnosis TerminatedThis study aimed to develop and validate a tablet-based eye-tracking app to detect cancer-related cognitive impairment, often called 'chemo brain.' Researchers planned to enroll 230 participants, including breast cancer patients scheduled for chemotherapy and healthy volunteers. …
Sponsor: Innodem Neurosciences • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
Quick MRI scan could spot breast cancer earlier in dense breasts
Diagnosis TerminatedThis study tested a new, fast, and low-cost MRI method for breast cancer screening in women with dense breasts or moderate risk. The goal was to see if this MRI could find cancers earlier and more accurately than standard mammograms. The study enrolled 166 women and compared MRI …
Sponsor: University of Chicago • Aim: Diagnosis
Last updated Jun 27, 2026 11:04 UTC
-
Skin-Saving paste for cancer radiation falls short in tiny trial
Prevention TerminatedThis study tested whether Alkagin paste could prevent skin damage in patients receiving radiation for anal, rectal, or gynecological cancers. Only 2 people enrolled before the trial was stopped early. Because of this, we cannot draw any reliable conclusions about the paste's effe…
Phase: PHASE2 • Sponsor: Sir Mortimer B. Davis - Jewish General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
Pre-Surgery pelvic floor training may prevent devastating bowel issues in rectal cancer patients
Prevention TerminatedThis study looked at whether doing pelvic floor exercises with biofeedback before rectal cancer surgery could prevent a condition called Low Anterior Resection Syndrome (LARS), which causes bowel control problems like leakage and urgency. The study planned to include 120 adults a…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:10 UTC
-
Blood pressure drug tested to prevent transplant complication
Prevention TerminatedThis pilot study tested the blood pressure drug telmisartan (Micardis) to prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. The trial aimed to enroll 60 participants but was terminated early with 32. Researchers tracked s…
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Prevention
Last updated Jun 27, 2026 12:03 UTC
-
Could a High-Tech headband clear the fog of chemo brain?
Symptom relief TerminatedThis study tests whether a headband with special semiconductors can help with memory and thinking problems (often called 'chemo brain') in people who have had breast or gynecologic cancer. About 50 participants will wear either the active headband or a placebo version for 18 hour…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Aug 18, 2026 02:00 UTC
-
Sleep drug studied for breast cancer Survivors' insomnia
Symptom relief TerminatedThis study tested whether the sleep medication suvorexant (20 mg) could help breast cancer survivors who have trouble sleeping. Participants were postmenopausal women taking hormone-blocking drugs. The study was stopped early after enrolling only 5 people, so results are limited.
Phase: PHASE4 • Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Booklets beat anxiety? new study tests simple tool for breast cancer patients
Symptom relief TerminatedThis study is testing whether giving women with early-stage breast cancer two easy-to-read booklets can help lower their anxiety after diagnosis. The booklets explain the disease and treatments in a gentle, clear way. About 60 women will take part, and researchers will measure ho…
Sponsor: Institut de Cancérologie de Lorraine • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Wakefulness drug shows promise for brain tumor fatigue, but study stalls
Symptom relief TerminatedThis study tested a drug called solriamfetol to see if it could safely help people with brain tumors (gliomas) feel more awake, think clearer, and have a better quality of life. Only 2 people enrolled before the study was stopped early. The main goal was to check for serious side…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Which bypass surgery helps cancer patients eat solid food again?
Symptom relief TerminatedThis trial compares two types of stomach bypass surgery for people whose stomach is blocked by cancer. The goal is to see which surgery allows patients to eat solid food better within the first 30 days. Participants are randomly assigned to one of the two procedures, and their st…
Phase: NA • Sponsor: Corewell Health West • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
New sedative could speed recovery for ventilator patients
Symptom relief TerminatedThis study tests a new sedative called remimazolam for people in the ICU who need a breathing tube after oral or facial surgery. It compares remimazolam to two standard sedatives, propofol and midazolam, to see if it works just as well and helps patients wake up faster. The trial…
Phase: PHASE4 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Could skipping the chest tube after lung surgery cut pain and hospital time?
Symptom relief TerminatedThis trial investigates whether removing the chest tube during thoracoscopic lung surgery, instead of leaving it in place afterward, leads to less pain and faster recovery. Participants undergoing elective wedge resection are randomly assigned to have the tube removed during surg…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Can a simple video ease the fear of breast cancer surgery?
Symptom relief TerminatedThis study investigates whether giving patients personalized, secure access to a web platform with an explanatory video about their upcoming breast cancer surgery can lower their anxiety. Participants are women with breast cancer scheduled for lumpectomy, oncoplasty, or mastectom…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Short radiation course for rectal cancer aims to ease side effects
Symptom relief TerminatedThis study tested a short course of targeted radiation (IMRT) given over one week before surgery for rectal cancer. The goal was to see if this approach could reduce side effects like bowel problems and improve quality of life compared to standard longer treatments. Only 2 people…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
App aims to get breast cancer patients moving during chemo
Symptom relief TerminatedThis study tested a smartphone app called 'Bouge' to see if it could help women with non-metastatic breast cancer increase their daily steps while on weekly Taxol chemotherapy. The goal was to add 3,000 steps per day over 90 days. Only 23 people enrolled, and the trial was stoppe…
Phase: NA • Sponsor: University Hospital, Brest • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New pain block aims to cut opioid use after kidney surgery
Symptom relief TerminatedThis study looked at whether adding an ultrasound-guided ESP nerve block to standard pain medicine could reduce opioid use and improve pain control after laparoscopic kidney removal for cancer. Ten adults having keyhole kidney surgery were enrolled. The study was stopped early, s…
Phase: NA • Sponsor: McMaster University • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Brain tumor drug trial fizzles: only 3 patients enrolled
Symptom relief TerminatedThis early-phase trial tested whether brivaracetam, a seizure medication, is safe for people with diffuse gliomas (a type of brain tumor). Only 3 participants were enrolled before the study was terminated. The main goal was to track side effects, not to measure tumor shrinkage or…
Phase: EARLY_PHASE1 • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Exercise program for myeloma patients shows promise but study ends early
Symptom relief TerminatedThis study looked at whether a supervised exercise program could help improve quality of life and reduce fatigue in people under 65 with multiple myeloma who had a stem cell transplant. Participants were randomly assigned to either an exercise group or a control group. The study …
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
Could a simple TENS device ease chemo nerve pain?
Symptom relief TerminatedThis trial tested whether a TENS device, which sends mild electrical pulses to the skin, can help relieve nerve pain caused by chemotherapy in early-stage breast cancer patients. The study enrolled 17 people who were having taxane chemotherapy and had at least mild nerve pain in …
Phase: NA • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Mouthwash may fight Chemo's bitter side effect
Symptom relief TerminatedThis pilot study tested a mouthwash made with homoeriodictyol sodium to reduce bitter taste caused by chemotherapy in women with gynecologic cancers. The study aimed to see if the mouthwash could improve taste and food intake. Only 15 participants were enrolled, and the trial was…
Phase: NA • Sponsor: Christoph Grimm • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Step counts may predict trouble during lung cancer therapy
Symptom relief TerminatedThis study tested whether monitoring daily step counts in people with stage III non-small cell lung cancer during chemoradiotherapy helps doctors provide better supportive care and reduce hospital stays or treatment delays. Only 3 participants were enrolled before the study was s…
Phase: NA • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
New program aims to boost Well-Being in young black breast cancer survivors
Symptom relief TerminatedThis study tested a program called Y-AMBIENT designed to improve quality of life for young African American women who finished treatment for early or late-stage breast cancer. The program included educational sessions and check-ins, compared to a control group that received a coo…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Exercise program for advanced lung cancer patients shows promise
Symptom relief TerminatedThis study looked at whether a supervised exercise program is possible for people with advanced bronchial cancer or mesothelioma. The goal was to see if patients could complete at least 6 rehab sessions to help with weakness and poor quality of life caused by the disease and its …
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New program aims to ease daily life for young black women battling breast cancer
Symptom relief TerminatedThis pilot study tested a four-month telephone program called Y-AMBIENT for young African American women (ages 18-44) with stage I-III breast cancer who were undergoing chemotherapy or radiation. The program included education sessions, follow-up calls, and videos to help manage …
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can less pressure mean better fibroid surgery?
Symptom relief TerminatedThis study looked at whether using a lower fluid pressure (60 mmHg) during hysteroscopy, a procedure to remove fibroids, works as well as the standard pressure (80 mmHg). The goal was to see if it improves surgery time, fluid use, and surgeon's view. The study was stopped early a…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Exercise study for advanced lung cancer falls short
Symptom relief TerminatedThis study looked at whether a program combining different types of exercise could help people with advanced lung cancer feel less tired, move better, and have a better quality of life. It was designed for adults with stage III or metastatic non-small cell lung cancer who were al…
Phase: NA • Sponsor: Indiana University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Experimental combo therapy for brain metastases shows early safety signals
Symptom relief TerminatedThis early-stage trial tested whether adding a device that creates electric fields (NovoTTF-200M) to standard radiation and immunotherapy is safe for people with melanoma that has spread to the brain. Only one person took part before the study was stopped early. The main goal was…
Phase: PHASE1 • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Pain pump after breast surgery: hope for faster recovery?
Symptom relief TerminatedThis study tested whether a continuous drip of the local anesthetic ropivacaine into the surgical wound after mastectomy could improve pain control and speed up recovery. The trial planned to enroll 59 women and follow them at home after discharge. However, the study was terminat…
Phase: PHASE3 • Sponsor: Institut Paoli-Calmettes • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Fewer radiation sessions may mean fewer side effects for prostate cancer patients
Symptom relief TerminatedThis study looked at men with low or intermediate-risk prostate cancer to see if 2 MRI-guided radiation treatments cause fewer bowel and bladder side effects than 5 treatments. The goal was to find a shorter treatment plan that is just as safe and less bothersome. The study was s…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Can a smartphone app help breast cancer patients stay on track with Life-Saving pills?
Symptom relief TerminatedThis study tested whether a web-based app could help women with early-stage hormone-positive breast cancer take their daily hormone therapy more consistently. Many patients stop taking these pills due to side effects or lack of support, which raises the risk of cancer returning. …
Phase: NA • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Newer radiation technique may spare bladder and bowel in endometrial cancer patients
Symptom relief TerminatedThis trial compared two ways of giving pelvic radiotherapy after surgery for endometrial cancer: standard 3D planning versus a newer technique called IMRT. The goal was to see if IMRT could reduce side effects like bladder and bowel problems. The study enrolled 92 participants bu…
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
New radiation technique may ease side effects for rectal cancer patients
Symptom relief TerminatedThis study compared two types of radiation therapy given before surgery for locally advanced rectal cancer. The goal was to see if a newer technique called IMRT causes fewer bowel side effects than the standard 3-D conformal radiotherapy. The trial enrolled 94 patients but was te…
Phase: PHASE1, PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Can early counseling help breast cancer survivors get back to work?
Symptom relief TerminatedThis study tested whether early, personalized support from a psychologist could help women with breast cancer return to work more successfully than standard support. The study included 128 women who had surgery and chemotherapy. Unfortunately, the trial was stopped early, so we h…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
CBD anxiety trial for brain cancer patients ends early
Symptom relief TerminatedThis study aimed to see if a high-CBD hemp product could reduce anxiety and improve quality of life in people newly diagnosed with glioblastoma, a serious brain tumor. The trial planned to compare the CBD product to a placebo over 8 weeks, but it was stopped early after only 2 pe…
Phase: PHASE2 • Sponsor: Mclean Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Can retelling and deep breathing ease trauma in terminal cancer?
Symptom relief TerminatedThis Phase 2 trial tested a neuroscience-based technique combining memory structuring and deep vagal breathing to reduce PTSD symptoms in people with advanced, incurable cancer and their partners. The study enrolled 19 patients who had just received a terminal diagnosis. The appr…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
New scan may reveal if cancer treatment is working
Knowledge-focused TerminatedThis study is testing whether a special PET scan called 18F-FSPG can help doctors see how well chemotherapy and radiation are working in people with esophageal cancer. Nine adults with untreated, locally advanced esophageal cancer will get the scan before and during treatment. Th…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Scientists dive into rare cholesterol disorders to uncover clues
Knowledge-focused TerminatedThis study looks at rare genetic disorders where the body can't make cholesterol properly, which can cause birth defects and learning problems. Researchers collect blood, urine, and tissue samples from affected people and their families to learn more about these conditions. The g…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Blood protein clues could personalize breast cancer care
Knowledge-focused TerminatedThis study investigates whether levels of certain blood proteins—VEGF, soluble HER2, and VCAM-1—change over time in women with hormone-insensitive breast cancer. It compares women who receive maintenance chemotherapy with those who do not, and also looks at whether these protein …
Phase: NA • Sponsor: ETOP IBCSG Partners Foundation • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
MRI might reveal hidden pancreatic risks in obesity
Knowledge-focused TerminatedThis study investigates whether MRI can detect early signs of pancreatic damage linked to obesity and metabolic syndrome, which are risk factors for pancreatic cancer. Researchers will compare MRI images with tissue samples from patients undergoing pancreatic surgery, as well as …
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Fat Tissue's hidden powerhouse: location may shape metabolism
Knowledge-focused TerminatedThis study investigates how the location of fat tissue in the body—under the skin versus around the organs—affects the function of mitochondria, the energy-producing parts of cells. Researchers will collect small samples of fat tissue from patients undergoing certain abdominal su…
Phase: NA • Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Biopsies may reveal why some cancers respond to immunotherapy
Knowledge-focused TerminatedThis study is looking at whether tumor biopsies can help predict which patients with melanoma, non-small cell lung cancer, or head and neck cancer will respond to immunotherapy drugs called PD-1 or PD-L1 inhibitors. Researchers will collect tissue samples from about 152 adults be…
Phase: NA • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Could a blood chemical explain bone pain in breast cancer?
Knowledge-focused TerminatedThis study looks at whether levels of histamine, a chemical in the blood, are linked to bone pain in people with breast cancer that has spread to the bones. Researchers will collect blood samples from participants and compare histamine levels with pain scores, including in those …
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Antifungal drug tested against brain tumors – trial stopped early
Knowledge-focused TerminatedThis early-phase trial tested whether the antifungal drug ketoconazole could block a protein called tGLI1 in brain tumors. It included 15 people with breast cancer that spread to the brain or with a type of brain cancer called glioma. The study was terminated early, so we have li…
Phase: EARLY_PHASE1 • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can 3D motion capture reveal hidden breathing problems after esophageal cancer surgery?
Knowledge-focused TerminatedThis study investigates how chest wall movement and lung function change in people who had open surgery for esophageal cancer more than a year ago, compared to healthy volunteers. Researchers use a 3D motion capture system and wearable sensors to track chest movement during breat…
Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Could a genetic marker guide future cancer therapies in taiwan?
Knowledge-focused TerminatedThis study is measuring how often a specific genetic marker (HLA-A*02:01) and a cancer-related protein (NY-ESO-1) appear in Taiwanese patients with solid tumors like head and neck, liver, lung, breast, and esophageal cancers. By understanding these frequencies, researchers hope t…
Sponsor: PharmaEssentia • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Brain electrode recordings during awake surgery could sharpen tumor removal
Knowledge-focused TerminatedThis study investigates whether recording brain electrical activity during awake surgery can help identify networks involved in thinking and language. In people with glial brain tumors located in critical functional areas, surgeons place electrode grids on the brain before waking…
Phase: NA • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Which scan best spots remaining tumor after chemo?
Knowledge-focused TerminatedThis study looked at 42 women with advanced breast cancer who had chemotherapy before surgery. It compared three imaging tests—PET-CT, ultrasound, and MRI—to see which one best measures leftover tumor. The goal was to help doctors choose the right surgery, but the study was stopp…
Phase: NA • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
How does a blood disorder drug perform in everyday practice?
Knowledge-focused TerminatedThis study looks at how the drug luspatercept is used in real-world clinics for patients with lower-risk myelodysplastic syndromes (MDS) or beta-thalassemia. Researchers will track patient characteristics, treatments, and outcomes like reduced need for blood transfusions. The goa…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
What drives cancer patients to try alternative therapies? a new survey seeks answers
Knowledge-focused TerminatedThis study surveys colorectal cancer patients about their use of complementary and alternative medicines (CAM), such as acupuncture, homeopathy, or dietary supplements. Researchers aim to understand which patients use CAM, why, and how it might affect their quality of life and ca…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Prostate cancer treatment may change how men process common sleep aid
Knowledge-focused TerminatedThis pilot study looked at how the sleep drug zolpidem (Ambien) is processed in men with prostate cancer before and after they start hormone therapy that lowers testosterone. Researchers compared these results to healthy women, since women are known to have higher drug levels. Th…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Liver damage study in head and neck cancer abandoned after just 2 patients
Knowledge-focused TerminatedThis study aimed to find out how often liver fibrosis and cirrhosis occur in people with head and neck cancer, since tobacco and alcohol are risk factors for both. Researchers planned to check liver health using exams and imaging. However, the study was stopped early after only 2…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Skin microbes linked to vitiligo and immunotherapy reactions in melanoma patients
Knowledge-focused TerminatedThis study explores whether the community of bacteria living on the skin (the skin microbiome) plays a role in vitiligo—a condition that causes white patches—and in side effects from anti-PD-1 immunotherapy for advanced melanoma. Researchers will collect skin swabs from people wi…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
COVID-19 vaccine safety checked in cancer immunotherapy patients
Knowledge-focused TerminatedThis study aimed to see if COVID-19 vaccines cause more side effects in cancer patients receiving immunotherapy. Researchers planned to track 125 patients from several hospitals in France, recording any local or systemic side effects. The study was terminated early, so the full r…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Hysterectomy study abandoned after just one patient
Knowledge-focused TerminatedThis study aimed to compare how often women could go home the same day after a hysterectomy using three different minimally invasive techniques: vNOTES (through the vagina), conventional laparoscopy, and robot-assisted laparoscopy. The trial was terminated early after enrolling o…
Phase: NA • Sponsor: Elsan • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Tiny study hopes to predict blood cancer risk from genetic mutations
Knowledge-focused TerminatedThis study aimed to find genetic mutations in people with idiopathic cytopenia of undetermined significance (ICUS), a condition of unexplained low blood cell counts. Researchers wanted to see if these mutations are similar to those found in myelodysplastic syndrome (MDS), a type …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study checks if stopping a drug made polyps grow faster
Knowledge-focused TerminatedThis study reviewed medical records of 42 people with familial adenomatous polyposis (FAP) who had previously taken the drug erlotinib. Researchers wanted to see how quickly the disease progressed after the drug was stopped. The goal was to better understand what happens when tre…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Antibiotic resistance explored in myeloma stem cell transplants
Knowledge-focused TerminatedThis study aimed to find out how common antibiotic resistance is in multiple myeloma patients receiving a stem cell transplant. Researchers planned to collect data from 124 adults to help design future studies on preventing infections. The study was stopped early, so results are …
Sponsor: Hackensack Meridian Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Can pictures help patients understand research better?
Knowledge-focused TerminatedThis study tested whether a visual consent form with pictures helps patients with cancer or Alzheimer's understand research better than standard text. Researchers planned to enroll 266 adults across three U.S. sites. The trial was terminated early, so results may be limited.
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Robot-Assisted brain biopsy study ends early – only 4 patients enrolled
Knowledge-focused TerminatedThis study looked at whether a robotic navigation device can help doctors take brain biopsies accurately. The goal was to see if the robot could achieve a 90% success rate in getting a clear tissue sample. Only 4 people with brain tumors took part before the study was stopped. Th…
Sponsor: Brainlab AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New imaging technique could let doctors see lung Cancer's inner workings in real time
Knowledge-focused TerminatedThis early-phase study tested whether two optical imaging agents could be used during a bronchoscopy to visualize activated neutrophils and a cancer-related protein called c-MET in lung tumors. Five participants with lung cancer received the agents through a special catheter whil…
Phase: EARLY_PHASE1 • Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Fitness trackers vs. Doctor's eye: which better gauges cancer Patients' mobility?
Knowledge-focused TerminatedThis study tested whether consumer movement trackers could provide a more precise measure of cancer patients' physical abilities than the standard ECOG score, which relies on a doctor's observation. Researchers enrolled 41 cancer patients and used a Kinect device to record their …
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Nano-X rotation study for cancer patients ends early
Knowledge-focused TerminatedThis study looked at how cancer patients experience being rotated horizontally in the Nano-X system. 43 patients completed questionnaires about anxiety and motion sickness before and after rotation. The study was terminated early, so findings are limited.
Phase: NA • Sponsor: University of Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Can a simple online Check-In help cancer patients cope?
Knowledge-focused TerminatedThis study tested whether a web-based screening tool could help monitor depression and distress in adults who had surgery for new head and neck cancer. Participants were randomly assigned to use the tool or receive usual care. The goal was to see if the tool led to more timely me…
Phase: NA • Sponsor: University of Alberta • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Blood test hope for liver cancer diagnosis
Knowledge-focused TerminatedThis study looked at whether two tiny molecules, called miR-221 and miR-222, can be found in the blood of people with liver cancer. Researchers wanted to see if these molecules could help diagnose the disease without needing a liver biopsy. The study was very small, with only 10 …
Sponsor: University of Aberdeen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Scientists hunt for hidden cancer genes in young patients
Knowledge-focused TerminatedThis study aimed to find inherited gene changes in people diagnosed with cancer at a young age, including breast, ovarian, colorectal, and pediatric cancers. Researchers used a special test to look at 200 genes linked to cancer in 289 participants. The goal was to better understa…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Immune system secrets in advanced breast cancer under the microscope
Knowledge-focused TerminatedThis observational study aimed to measure different types of immune cells in women with advanced breast cancer that has spread. Researchers collected blood and leftover tumor samples to see how these cells change over time. The study was terminated early, so only a small number o…
Sponsor: Spanish Breast Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Lung cancer study aims to predict dangerous lung inflammation
Knowledge-focused TerminatedThis study followed 83 people with advanced non-small cell lung cancer who were starting standard treatments. The goal was to collect information to help develop a digital tool that can spot early signs of pneumonitis/ILD, a serious lung inflammation that can occur as a side effe…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Eye test may forecast kidney failure after cancer surgery
Knowledge-focused TerminatedThis study looked at whether special eye scans (OCT-angiography) can predict how well the remaining kidney will work one year after kidney removal for cancer. Researchers enrolled 30 adults scheduled for total nephrectomy. The goal was to see if retinal blood vessel patterns coul…
Phase: NA • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Smell test after brain surgery: what surgeons learned
Knowledge-focused TerminatedThis study looked at how a person's sense of smell changes after endoscopic endonasal skull base surgery, a procedure done through the nose to remove tumors or other abnormalities. Researchers measured smell using a simple identification test in 50 patients before and after surge…
Sponsor: Ricardo L. Carrau, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New tool aims to help seniors with dementia make safer choices about guns
Knowledge-focused TerminatedThis pilot study tested a decision aid designed to help older adults with early dementia or depression think about safer ways to store firearms at home. Only 5 people took part, and the study was ended early. The goal was to see if the tool was practical and acceptable, and wheth…
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Superhero training for food allergy safety falls short
Knowledge-focused TerminatedThis study aimed to help children aged 6-8 from low-income families learn how to avoid foods they are allergic to. The program used fun, hands-on activities to teach safety skills. The study was stopped early, so we don't have clear results on whether it worked.
Phase: NA • Sponsor: Kent State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for genetic secrets in breast cancer tumors
Knowledge-focused TerminatedThis study aimed to find genetic and protein changes in breast cancer that could help predict how the disease behaves. Researchers collected tumor samples from 749 adults with breast cancer and analyzed them for gene activity and mutations. The study was stopped early, so results…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Spinal tap could replace brain surgery for young tumor patients
Knowledge-focused TerminatedThis study looked at whether a liquid biopsy—testing the fluid around the brain and spinal cord—can find tumor DNA in children and young adults with brain tumors. The goal was to see if this safer, non-surgical test could replace risky tissue biopsies for diagnosis and monitoring…
Sponsor: Pediatric Brain Tumor Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New registry aims to sharpen liver tumor ablation techniques
Knowledge-focused TerminatedThis study tracked over 1,200 people with liver cancer who received microwave ablation, a procedure that uses heat to destroy tumors. Researchers collected data over 5 years to see how well the ablation worked and how long patients lived. The goal was to create better guidelines …
Sponsor: Ethicon, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Kidney cancer drug study halted after just 6 patients
Knowledge-focused TerminatedThis study aimed to see if the amount of sunitinib in the blood affects side effects and how well the drug works in people with metastatic kidney cancer. Researchers planned to collect extra blood samples during routine visits from patients starting sunitinib as their first treat…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Weight may influence breast cancer drug response, study suggests
Knowledge-focused TerminatedThis study looked at whether body weight affects how breast cancer responds to aromatase inhibitors (AIs) like Anastrozole and Letrozole. Researchers gave standard doses of these drugs to 42 postmenopausal women with hormone-sensitive breast cancer before surgery. The goal was to…
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Stomach cancer clues sought in hispanic population study
Knowledge-focused TerminatedThis study aimed to find genetic and lifestyle factors that increase stomach cancer risk in a mostly Hispanic population in South Texas. Researchers compared DNA from cancer tissue and saliva, and surveyed patients about diet, health history, and exposures. The goal was to unders…
Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Massive myeloma registry ends early, but data may still inform care
Knowledge-focused TerminatedThis study was a large registry that followed over 3,000 people newly diagnosed with multiple myeloma to understand how the disease is managed in everyday practice. Participants received standard treatments prescribed by their own doctors, and researchers collected information on…
Sponsor: Celgene • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Tiny study on brown fat and cancer metabolism halted early
Knowledge-focused TerminatedThis pilot study aimed to understand how brown adipose tissue (brown fat) might contribute to weight loss in cancer patients. Researchers planned to measure energy use in patients with and without active brown fat. However, the study was terminated early and only enrolled 3 parti…
Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
New PET tracer aims to spy on immune cells fighting cancer
Knowledge-focused TerminatedThis pilot study tested whether a new PET imaging tracer called [18F]F-AraG could track immune T cells inside tumors of patients with advanced solid cancers who were receiving immunotherapy. Nine patients were enrolled to have PET scans and tumor biopsies before and after treatme…
Phase: PHASE2 • Sponsor: CellSight Technologies, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Scientists hunt for cancer clues in blood particles
Knowledge-focused TerminatedThis study looked at tiny particles called exosomes in the blood of 172 colorectal cancer patients. Researchers wanted to see if the contents of these particles could help predict survival and cancer spread. The goal was to find new biomarkers that could be measured with a simple…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Lung cancer imaging study halted early
Knowledge-focused TerminatedThis pilot study aimed to see if combining PET and MRI scans could better show tumor differences in non-small cell lung cancer (NSCLC). Only 11 people were enrolled before the study was stopped early. The goal was to check if the imaging method was consistent when used by differe…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Scientists investigate why some breast cancer cells survive chemo
Knowledge-focused TerminatedThis study looked at how breast cancer stem cells—cells that can resist treatment and cause cancer to return—emerge during chemotherapy. Researchers collected blood and tumor samples from 56 women before, during, and after treatment to analyze genetic changes. The goal was to und…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Chemotherapy breakthrough? study cut short for esophageal cancer patients
Knowledge-focused TerminatedThis study aimed to find out if patients with metastatic esophageal cancer who were not getting worse after 6 weeks of chemotherapy should continue treatment or stop. It included 15 adults whose cancer had spread and was no longer responding to initial chemo. The study was termin…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Blood test vs. needle biopsy: can a simple draw detect lung cancer mutations?
Knowledge-focused TerminatedThis study looked at whether a blood test (liquid biopsy) could find EGFR gene mutations in lung cancer patients as accurately as a standard tumor biopsy. Researchers planned to enroll 21 patients with advanced lung cancer who had not yet received treatment. The study was termina…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Ovarian cancer immune cells under microscope in terminated study
Knowledge-focused TerminatedThis study aimed to understand how immune cells in the blood, abdominal fluid, and tumor tissue change in women with advanced ovarian or fallopian tube cancer before and after chemotherapy. Researchers collected samples from 36 women to count different types of immune cells. The …
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Sarcoma lung surveillance study halted early: x-ray vs CT debate unresolved
Knowledge-focused TerminatedThis study aimed to compare chest X-ray and CT scans for detecting lung metastases in people who had surgery for high-grade soft tissue sarcoma. Only 11 patients were enrolled before the study was terminated early. The goal was to see which method better finds isolated, operable …
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Scientists test a 'non-stick' patch from body cells to stop surgical scars
Knowledge-focused TerminatedThis lab study tested two types of human cells to see which could best form a non-stick patch to prevent internal scar tissue after cancer surgery. Researchers collected cells from the peritoneum (lining of the abdomen) and from fat tissue, then grew them in the lab. The study wa…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Brain tumor radiation study halted early – what it means for patients
Knowledge-focused TerminatedThis study aimed to track quality of life in 52 patients with brain metastases who received radiosurgery (Gamma Knife). Patients filled out questionnaires before treatment and every 3 months for a year. The study was terminated early, so the full impact on daily life remains uncl…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Chemo's toll on fertility: study in young breast cancer patients
Knowledge-focused TerminatedThis study aimed to understand how chemotherapy impacts the ability to have children in young women (ages 18-37) with breast cancer. Researchers measured ovarian reserve (egg supply) using hormone levels and follicle counts before, during, and up to 24 months after treatment. The…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Skin cancer surveillance study ends early after just one patient
Knowledge-focused TerminatedThis study aimed to see if regular ultrasound scans of lymph nodes could detect the spread of high-risk skin cancer on the head or neck earlier than usual. It planned to enroll patients with aggressive tumors or weakened immune systems. However, the study was terminated after onl…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC